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ABSTRACT 
The TRH (thyrotropin releasing hormone) stimulation test is emerg¬ 
ing as a promising test in biological psychiatry. A diminished, or 
blunted, response of TSH (thyroid stimulating hormone) to an infusion of 
TRH has been reported in approximately 25% of depressed patients. This 
response is also seen in some manics, and the test is reported to be 
helpful in distinguishing mania from acute schizophrenia, an important 
clinical differential diagnosis. 
One factor which may influence the TRH test in psychiatric patients 
is antipsychotic medication, since most of these medications are known 
to affect dopaminergic activity. Experimental evidence suggests that 
dopamine (DA) reduces TSH response to TRH. The existing small number of 
studies on the effects of antipsychotics on the TRH test in schizophren¬ 
ics disagree, and clarification of this question would be useful to the 
clinician who may have to perform the TRH test on patients who are 
receiving antipsychotics. 
A standardized TRH test was administered to 19 male patients and 14 
healthy controls. Eight of the patients were on no medications, and 11 
were on antipsychotics. The patients included 11 diagnosed by RDC as 
schizophrenic and 8 schizoaffectives, roughly evenly distributed between 
antipsychotic/no antipsychotic groups. The subject groups were matched 
with respect to demographic variables such as age, height, and weight, 
as well as baseline TSH and total serum thyroxine (TT4). The TSH 
response, as measured by the maximum increment of TSH over baseline 
(ATSHmax) as well as area under the two hour curve of TSH response, was 
not significantly different between patients on or off antipsychotics as 
well as between either patient group and normal controls. Blunted 
ATSHmax responses were seen in 3/8 unmedicated patients, 3/11 patients 
on antipsychotics, and 2/14 controls. Antipsychotic dosage, and the 
duration of treatment were not found to confound the test results. The 
responses of the schizophrenics were not found to differ significantly 
from the schizoaffectives as a whole, nor did they differ in the antip¬ 
sychotic/no medications groups. The mean serum free thyroxine (FT4) was 
slightly lower in patients on no medications compared to controls, which 
is consistent with other studies finding subtle thyroid abnormalities in 
many euthyroid patients with physical and psychiatric disorders. Also, 
patients on antipsychotics had a significantly higher baseline prolactin 
(PRL), as would be expected. 
This study provides further evidence that antipsychotics do not 
affect the TSH response to TRH stimulation. It also found no differ¬ 
ences between schizophrenics and schizoaffectives on the TRH test, 
whether on or off antipsychotics, and found no differences between these 
patients and normal controls. These findings suggest that the TSH 
response to TRH may still be a reliable test, even if the patient being 
tested is concurrently being treated with antipsychotics medications. 
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I. PURPOSE 
The thyrotropin releasing hormone (TRH) stimulation test is becoming 
more widely used in psychiatry. Many psychiatric patients are receiving 
antipsychotic medications, but few studies have looked at the effects of 
these medications on the TRH test, and those studies which have been 
done have reported varying results. Therefore, this study was designed 
to investigate the influence of antipsychotics on the TRH test in schiz¬ 
ophrenic and schizoaffective patients. 
II. HYPOTHESIS 
The hypothesis of this study was that: (a) antipsychotic medications do 
not significantly modify the thyroid stimulating hormone (TSH) response 
to TRH stimulation in schizophrenic or schizoaffective patients, and 
therefore: (b) whenever needed, the TRH test can be performed on these 
patients with a considerable degree of reliability and confidence in the 
results as far as the TSH response is concerned. 
III. INTRODUCTION 
A. Biological Basis of Psychiatric Illness 
1) A brief overview 
One of the ultimate goals of researchers studying human behavior is to 
understand the functioning of the brain down to a biological level, both 
in health and in psychiatric disorders. However, the brain's immense 
complexity does not yield easily to study. After effective psychotropic 
drugs were discovered several decades ago and researchers gained a basic 
understanding of their mechanisms of action, it appeared that biological 
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explanations for at least the major psychiatric disorders might soon be 
at hand (eg. Schildkraut, 1965). Excesses or deficiencies of one or 
more neurotransmitter was proposed as the basis of some forms of mental 
illness, and such notions would fit nicely with the known actions of 
certain psychotropic medications. However, it soon became clear that 
single neurotransmitters do not exist in a vacuum. Each is influenced 
and in turn exerts its influence on other pathways involving other 
transmitters in an ever-expanding manner, which has been compared to the 
ripple of a stone thrown into a pond. 
Despite the oversimplification of the original biological hypotheses, 
they have been very successful in stimulating research. As new discov¬ 
eries are made the theories are modified, new hypotheses are generated 
and further research is undertaken (Alpert and Friedhoff, 1980). The 
result has been greatly increased knowledge of brain function, resulting 
in better pharmacological agents and more precise applications of exist¬ 
ing ones. Another likely outcome will be improvement in diagnosis as 
various homogeneous subtypes of the major diagnostic categories become 
better characterized, and diagnostic tests are perfected. This would 
allow therapy to be individualized with a higher probability of success. 
Disturbances in the CNS associated with psychiatric disorders may 
have characteristic effects on the neuroendocrine axis. Thus measure¬ 
ment of neuroendocrine parameters is becoming increasingly important in 
making certain diagnoses and predicting outcomes of treatment. Measure¬ 
ment of endocrine parameters is more feasible than the measurement of 
the dynamic activity of various neurotransmitters in the intact brain, 
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although PET-scanning may eventually place even this within the realm of 
possibility (Wagner, 1985). However, neuroendocrine parameters in psy¬ 
chiatric disorders are still incompletely understood, and thus the 
implications of many experimental findings are not yet quite clear. 
2) The dopamine hypothesis of schizophrenia 
There has been much written on the dopamine (DA) hypothesis of schi¬ 
zophrenia, and relevant research has been extensively reviewed by sev¬ 
eral authors (Meltzer and Stahl, 1976; Langer et al., 1981; Haracz, 
1982). The basic assertion of the hypothesis is that a central dopamin¬ 
ergic hyperactivity may underlie schizophrenia. Initial support for the 
hypothesis came from three main observations: (1) Effective antipsy¬ 
chotic medications block post-synaptic DA receptors and may therefore 
reduce central dopaminergic activity. (2) Dopamine agonists tend to 
exacerbate schizophrenia. (3) Amphetamines can produce a schizophrenia¬ 
like psychosis in normal persons which may be mediated through increased 
dopaminergic activity. There has been little direct support of the 
hypothesis, however. An extensive review of relevant research by Haracz 
(1982) concludes that studies trying to find direct evidence of DA-hy- 
peractivity are either unconvincing or are not widely replicated. These 
studies have examined DA or its metabolites in CSF, serum, or urine, or 
have attempted to quantitate DA, DA metabolites, or DA receptors in 
post-mortem brain tissue by a variety of methods. More recently, Rao et 
al. (1984) reported finding increased DA levels in the serum of schizo¬ 
phrenics. This finding has yet to be replicated however. 
3) The biogenic amine hypothesis of depression 
3 

Observations of the pharmacological action of various drugs lead to what 
became known as the catecholamine hypothesis of affective disorders 
(Schildkraut, 1965). Drugs that depleted functional levels of the brain 
catecholamines norepinephrine (NE) and serotonin (also known as 
5-hydroxytryptamine, or 5-HT), such as reserpine, were known to induce 
depression in some cases. Effective antidepressants including the tri¬ 
cyclics and MAO-inhibitors enhanced catecholamine activity. Thus it was 
hypothesized that depression was the result of a simple hypoactivity of 
one or several catecholaminergic systems. Direct evidence was not con¬ 
vincing, and there were other difficulties with the hypothesis including 
the observation that the time couse of drug effects on neurotransmitters 
does not coincide with theraputic effects (Bunney and Garland, 1981; 
Charney et al., 1981). Revised hypotheses of the biological basis of 
affective disorders have concentrated on secondary changes in transmit¬ 
ter activity levels and receptor function, and research activity is con¬ 
tinuing. 
4) Clinical implications 
Since neurotransmitters are known to control the release of hypothalamic 
tropic hormones and eventually pituitary hormones, researchers have been 
interested in studying how altered CNS activity may reflect itself 
through this "neuroendocrine window". In humans, measuring pituitary 
hormone levels is obviously more feasible than directly attempting to 
measure the levels of central neurotransmitters and pituitary response 
may give an accurate reflection of central activity. This may lead to 
the development of improved diagnostic tests that would be helpful in 
choosing therapy, and predicting outcome and long-term prognosis. 
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Distinguishing clinically among patients who are psychotically 
depressed, schizoaffective, schizophrenic or manic can be difficult at 
times; in fact these patients may appear indistinguishable at certain 
points during the course of their illnesses. The diagnosis may only 
become clear after several psychotic episodes and after long periods of 
time have elapsed. Many diagnostic criteria in use reflect this by 
including requirements for the minimum length of time that the illness 
must have been present in order to be assigned a particular diagnosis. 
There have been no reliable diagnostic tests in the past that have been 
able to categorize psychotic patients reliably, but research is continu¬ 
ing. In this regard, a number of psychoendocrine tests hold promise for 
use in psychiatry in defining homogeneous groups or subgroups of 
patients within these diagnostic categories. Examples of these tests 
include the dexamethasone suppression test and the TRH-stimulation test. 
Since depressed patients are known to have a high proportion of sub¬ 
normal responses to the TRH stimulation test and some studies have sug¬ 
gested similar findings in manics, while schizophrenics have generally 
been found to have normal responses, the TRH stimulation test may hold 
promise as a diagnostic tool in differentiating schizophrenics from 
patients with affective illnesses. A blunted response to the test might 
be helpful additional evidence in favor of a diagnosis of an affective 
disorder rather than schizophrenia. A normal response would be less 
helpful, since blunting is not universally present in depression and 
mania. However, it must be cautioned that the number of reported stud¬ 
ies on the TRH test in schizophrenics is still relatively small, even 
though most of them corroborate the above mentioned findings. 
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A factor which may have an impact on the potential usefulness of the 
TRH test is the effect of antipsychotic medications, which are widely 
prescribed to psychotic patients. There are theoretical reasons for 
suspecting that these drugs may influence the hypothalamic-pituitary- 
thyroid axis. Antipsychotics are DA-receptor blockers which cause 
changes in dopaminergic activity (Baldessarini, 1980), and DA is a known 
inhibitor of TSH release (Besses et al., 1975). Also, some antipsy¬ 
chotics interfere with the action of calmodulin, which has a role in 
mediating the cellular response to TRH stimulation in the thyrotropes 
(Drust and Martin, 1982). 
B. The Hypothalamic-Pituitary-Thyroid Axis 
Circulating levels of thyroid hormones are tightly controlled by homeos¬ 
tatic mechanisms. The major determinant of thyroid hormone release from 
the thyroid is TSH secreted by the pituitary. The secretion of TSH is 
mainly regulated by TRH, which is secreted by the hypothalamus and 
reaches the pituitary through the hypophyseal portal circulation. Neg¬ 
ative feedback of TSH release is affected by circulating thyroid hor¬ 
mones acting mainly on the anterior pituitary. Various other substances 
are known to have an effect on TSH secretion, but their relative impor¬ 
tance in the overall regulation of TSH secretion is not clear. 
1) TRH 
a) Chemistry. Thyrotropin releasing hormone (TRH) is a modified tri¬ 
peptide (pyroglutamyl-histidyl-proline amide). It is synthesized in the 
hypothalamus in the supraoptic and paraventricular nuclei (Reichlin, 
1981) and transported through the hypophyseal portal venous system. It 
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is also found diffusely throughout the brain, and in the spinal cord, 
CSF, and GI tract; in fact over 70% of total brain TRH is said to be 
outside the hypothalamus (Jackson, 1982). It is thought that the TRH in 
the CNS may be a neurotransmitter or neuromodulator, and Jackson notes 
that it has been reported to directly affect the electrical activity of 
neurons in culture. 
b) Effects on the anterior pituitary. TRH has a stimulatory affect on 
pituitary thyrotropes, augmenting the release of preformed TSH and also 
increasing its rate of synthesis. It has been said to determine the 
"set-point" of pituitary TSH secretion (Daughaday, 1981). 
TRH also has a stimulatory affect on lactotropes, increasing the 
release of prolactin (PRL) at levels similar to those causing increased 
secretion of TSH, but TRH is not thought to play an important role in 
the physiological control of PRL release. There also seems to be some 
affect of TRH on cells secreting growth hormone (GH) and adrenocortico- 
tropin (ACTH), but again this is not thought to be important physiologi¬ 
cally. A paradoxical rise in GH secretion is seen in response to TRH 
infusion in certain conditions including acromegaly, chronic renal fail¬ 
ure, and anorexia nervosa, as discussed in the section on TRH testing. 
c) Determinants of TRH release. The factors which stimulate and 
inhibit TRH release from the hypothalamus have not been entirely worked 
out. Thyroid hormones had been thought to exert a negative feedback 
inhibition on TRH as well as TSH but this is questioned by some. Wil¬ 
liams (1981) states "there is no convincing evidence that thyroid hor¬ 
mones directly modify the secretion of TRH." However, the presence of 
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both TSH and peripheral thyroid hormones seems to be necessary for TRH 
release (Roti et al., 1978). 
There is evidence that cold-induced TRH stimulation is under o- 
adrenergic control in the rat (Montoya et al., 1979). This study showed 
that NE stimulates TRH, and this effect can be diminished by pre-treat¬ 
ment with a-blockers. The effects of other neurotransmitters on TRH 
release, including DA, 5-HT, histamine, and the endorphins are contro¬ 
versial (Jackson, 1982). Serotonin appears to inhibit TRH release 
(Reichlin, 1981). Small doses of estrogen are known to greatly reduce 
the level of TSH, and this may occur by inhibiting TRH, whereas large 
doses, such as those found in contraceptives, cause an exaggerated TSH 
response to TRH (Reichlin, 1981). 
d) Other effects of TRH. Administration of TRH has certain behavioral 
effects in humans as well as in animals, despite the fact that peripher¬ 
ally injected TRH does not cross the blood brain barrier well (Jackson, 
1982). These effects may be a result of TRH activation of cholinergic 
or dopaminergic pathways. TRH appears to increase cholinergic activity 
in motoneurons in the spinal cord, and increases vagal (parasymathetic) 
tone (Yarbrough, 1983). This appears to be responsible for some of the 
stereotyped behaviors observed in animals, including the induction of 
tremors in rats and increased EMG in cats. It also increases parasym¬ 
pathetic outflow to the GI tract, iris, and thyroid, and has an analep¬ 
tic effect (Yarbrough, 1983). Because of its relation to the choliner¬ 
gic system, and the fact that the anticholinergic activity of 
antipsychotics is thought to be the basis of tardive dyskinesia (TD), 
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TRH was administered to rats with an animal model of TD. The amount of 
stereotyped movement was found to be reduced (Yarbrough, 1983). Usijima 
et al. (1984) also found TRH to induce a variety of stereotyped behav¬ 
iors in mice, some of which were reduced by prior administration of DA 
blockers, while others were reduced by anticholinergics. Lin et al. 
(1983) found evidence of cholinergic activation by TRH, but also found 
certain stereotyped behaviors to be modified by prior administration of 
an opiate antagonist, possibly implicating TRH in endorphin pathways as 
well as dompaminergic and cholinergic ones. 
In humans TRH administration was reported to cause certain transient 
behavioral effects such as a short-lived increase in feelings of well¬ 
being. In most psychiatric disorders there is also a a temporary 
improvement in symptoms. (Loosen et al., 1977; Inanaga et al., 1978; 
Loosen and Prange, 1980). This is discussed in more detail in the sec¬ 
tion on the TRH stimulation test. 
TRH is metabolized by rapid enzymatic breakdown in tissues and body 
fluids. One metabolite, histidyl-proline-diketopiperazine or His-Pro- 
DKP, has been found to have central activity (Jackson, 1982). 
2) TSH 
a) Chemistry. Thyroid stimulating hormone (TSH) is a glycoprotein of 
molecular weight 32,000. It is composed of two subunits, a and 0. The 
a-subunit contains 89 amino acid residues and is identical to the a-su- 
bunit of follicle stimulating hormone (FSH) and luteinizing hormone 
(LH). The 0-subunit, which is 112 amino acids long, confers specificity 
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to the molecule. TSH is released from thyrotrope cells of the adenohy¬ 
pophysis, which are located mainly in the anteromedial portion of the 
gland. 
b) Determinants of TSH release. There are several factors that effect 
TSH release, the most important of which are TRH and circulating thyroid 
hormones. 
TRH stimulates release of preformed TSH as well as increasing its 
synthesis and also causes down-regulation in the number of TRH receptors 
on the thyrotrope (Hinkle and Tashjian, 1975). TRH exerts its effects 
on the thyrotrope through binding to specific TRH receptors on the 
plasma membrane which have been characterized by Labrie et al. (1972). 
It appears that there may be distinctive populations of TRH receptors in 
the pituitary and the CNS, based on studies of tritiated-TRH binding 
characteristics (Simasko and Horita, 1984). The sequence of events fol¬ 
lowing TRH binding to its receptor and leading to TSH secretion is known 
to involve an increase in cytoplasmic calcium, probably from cytoplasmic 
pools (Drust and Martin, 1982). The calcium regulatory protein calmodu¬ 
lin is involved in mediating this response. A series of experiments by 
Fleckman et al. (1981) demonstrated that although the exact sequence of 
intracellular events has not been determined, calcium is intimately 
involved in TRH action, and probably serves as the "second messenger" in 
TSH secretion. Earlier researchers had suggested that cyclic adenosine 
monophosphate (cAMP) may serve as the second messenger, but the studies 
by Fleckman's and Drust's groups provided evidence to refute this 
hypothesis. The work by Drust and Martin also provided evidence that 
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certain cellular events stimulated by TRH seem to be independent of both 
calcium and cAMP, implying the possible existence of another second mes¬ 
senger. Since TRH is known to have several effects on pituitary cells 
including stimulating the secretion of preformed TSH, increasing the 
rate of TSH synthesis, and inducing changes in TRH receptor numbers, it 
seems reasonable that these effects may not all be mediated by the same 
second messenger. 
Triiodothyronine (T^) exerts a major inhibitory influence on TSH 
synthesis and secretion. It also reduces the number of TRH receptors on 
the thyrotropes (Larsen, 1982). The response to T^ seems to be mediated 
through a specific nuclear receptor. Protein synthesis is involved in 
the subsequent response, since protein synthesis inhibitors including 
cyclohexamide, puromycin, and actinomycin D have been shown to block the 
inhibitory effects of T^ (Larsen, 1982). However, it is known clini¬ 
cally that high levels of thyroxine (T^) as well as high T^ can inhibit 
TSH. This does not seem to fit with the finding that thyroid hormone 
receptors in TSH-secreting cells have an affinity for T^ many times 
greater than for T^. The explanation for this observation seems to be 
that pituitary tissue possesses an iodothyronine 5' deiodination enzyme 
that is distinct from the one found in liver and kidney (Silva et al., 
1982; Visser et al., 1983). Thus T^ can be converted to T^ within the 
pituitary cells even in the presence of agents which block conversion 
peripherally, such as propylthiouracil. The T^ formed intracellularly 
can then bind to its receptor and exert its inhibitory influence on TSH 
secretion. 
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Several other factors influence TSH secretion. Both DA (Scanlon et 
al., 1979) and somatostatin (Tanjasiri et al., 1976) have been shown to 
inhibit TSH release at the level of the pituitary. Cortisol also inhib¬ 
its TSH release; patients with untreated Cushing's disease as well as 
patients given pharmacological doses of glucocorticoids have been shown 
to have decreased TSH responses (Otsuki et al., 1973). The increased 
levels of GH found in acromegaly have been associated with a decreased 
TSH response to TRH, and GH deficiency has been reported to be associ¬ 
ated with an increased TSH responsiveness. However, it is thought that 
these effects may be caused by a "short feedback loop" of GH on hypoth¬ 
alamic somatostatin, which then affects the thyrotropes, rather than 
being the result of a direct GH effect (Jackson, 1982). Estrogen has 
been found to increase TSH secretion, while androgens decrease it. 
(Reichlin, 1981). 
c) Actions. TSH is bound by specific receptors on the plasma membrane 
of the thyroid cells and initiates a variety of actions including 
increased iodine uptake, increased thyroglobulin synthesis, increased 
release of thyroid hormones, and other effects. Basically, the general 
activity level of the thyroid cells is increased. The action of TSH on 
the thyroid is mediated by cAMP (Ingbar, 1981). 
C. The TRH Stimulation Test in Norma! Controls 
1) Overview 
The TRH stimulation test was originally developed for use in the diagno¬ 
sis of certain thyroid abnormalities. Interest in its use in psychiatry 
followed the finding by Prange et al. (1972) of an abnormally low TSH 
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response to TRH ("a blunted response") in a large fraction of depressed 
patients. This finding has since been replicated by many investigators 
(see Loosen and Prange, 1982, for a review). 
Interpreting the results of TRH testing in patients with psychiatric 
disorders requires a basic understanding of the test in normal controls. 
Many factors other than psychological state, such as age, sex, nutri¬ 
tion, and time of day may affect the results of the test, and should be 
considered before attributing observed differences in test results 
solely to psychopathology. 
The exact method used in TRH testing has not been standardized, and 
may contribute to some of the inconsistencies found in the literature, 
since the timing, dose of TRH, choice of dependent variables, and cri¬ 
teria for considering a response abnormal vary. There have been several 
reviews of the methodology of TRH testing (Snyder and Utiger, 1972; Loo¬ 
sen et al., 1982, 1983; Loosen and Prange, 1982;). 
The dose of TRH used in the test is obviously of major importance in 
determining the result observed. The minimum amount of TRH necessary to 
cause a measureable increase in TSH is approximately 6.25 yg (Snyder and 
Utiger, 1972). Increasing the dose of TRH increases the TSH response in 
a linear fashion between 100 and 400 yg, and a plateau in TSH response 
is seen at TRH levels above 400 yg (Loosen and Prange, 1982). A stan¬ 
dard TRH dose of 500 yg is therefore recommended by Loosen’s group, 
since a slightly supermaximal dose should insure a maximal response in 
all subjects, regardless of body weight, and will avoid some false posi¬ 
tive blunted responses. However, various researchers have used TRH 
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doses ranging from 200 to 800 yg, which makes comparisons of the results 
difficult. A dose of 200 yg will not induce a maximal response, and may 
cause a relatively smaller response in heavier patients due to a greater 
dilutional volume for the infused TRH. The present study used a TRH 
dose of 500 yg. 
The TSH response to a dose of TRH follows a fairly predictable 
course. The level of TSH rises fairly quickly after TRH administration 
from the normal baseline of 1.9-5.4 yU/ml, reaching a peak around 20-30 
minutes after injection, although in some individuals TSH may reach a 
peak as early as 15 minutes or as late as 60 minutes after injection 
(Snyder and Utiger, 1972). 
A variety of measures have been used to express the TSH response to 
TRH. Theoretically, the most accurate measure would be the area under 
the curve generated by plotting serum TSH levels against time from 
injection of TRH until TSH has returned to baseline (Wilkin et al., 
1979). See Appendix E for the appearance of a typical response curve. 
Since it is not possible to measure TSH levels at an infinite number of 
time points, most investigatiors have chosen a standard number of time 
points after TRH injection to measure TSH levels, ranging from one to 
six. The absolute level of TSH at each point is less informative than 
the change from the baseline value, or ATSH. Since calculating the area 
under the response curve is cumbersome, and would be inaccurate when 
only one or two points are used, most investigators have used some meas¬ 
ure of the change of TSH from baseline to quantify the response to TRH. 
The most widely used measure is the ATSH value at that time point corre- 
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sponding to the maximal response seen, or ATSH . The ATSH value is 
highly correlated with area under the curve of TSH response which indi¬ 
cates that it is an accurate measure of the TSH response (Loosen et al., 
1982). The ATSH is usually found to be from the sample taken at 30 
minutes after TRH infusion. Therefore, some studies have used the ATSH 
value of one sample taken at 30 minutes as a dependent variable. There 
is evidence that this is an acceptable measure of response, since values 
observed are highly correlated with the area under the curve values cal¬ 
culated from multiple samples (Wilkin et al., 1979). More recently, 
however, the use of this "short version" of the TRH test was cautioned 
against in depressed patients, where blunting of the response may be 
suspected, since the ATSH did not correlate well with the total area 
max 
under the curve (Wahby et al., 1985a). 
The criterion for an abnormal response to TRH infusion has also been 
defined differently by various investigators. While the normal ATSH 
considered to be approximately two times the baseline TSH level (Fish- 
bach, 1984), some responses are clearly subnormal, or "blunted". The 
ATSH values which have been used as the cutoff between a normal and a 
max 
blunted response range mostly from <5 yU/ml (Loosen and Prange, 1982) to 
17 uU/ral (Extein et al., 1980; Gold et al., 1981; Targum, 1983). The 
present study used <6 yU/ml as the cutoff. 
Another factor which may influence the percentage of blunted respon¬ 
ses seen is the technique used to determine serum TSH values. A compar¬ 
ison of two commonly used RIA techniques revealed that although the two 
techniques gave TSH values that were highly correlated with each other, 
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there was a significant difference between the actual values given by 
the two (Sternbach et al., 1983). 
There are no obvious similarities in persons with a blunted response 
in terms of height or weight. Some blunters have a low or low-normal 
baseline TSH value, and low thyroid hormone levels, suggesting a distur¬ 
bance in feedback inhibition (Loosen and Prange, 1983) 
The TRH stimulation test has generally been considered a very safe 
procedure, with the only side effects being mild and transient. The 
most common ones are a metallic taste in the mouth, a brief urge to mic¬ 
turate, nausea, and overall warmth. There have been few reports of more 
serious side effects. In a series of over 1500 TRH tests, Dolva et al. 
(1983) report only four instances of major reactions to TRH administra¬ 
tion. The reactions included loss of consciousness, hypotension, and 
seizure. All four patients recovered completely in less than 24 hours. 
As mentioned, some behavioral effects may accompany TRH administra¬ 
tion. These include mild euphoria and improvement in mental status in 
controls, and improvements in symptoms of some psychiatric patients, 
except in some paranoid schizophrenics (Loosen and Prange, 1980). A 
study of 143 chronic schizophrenic patients given TRH found significant 
improvement in symptoms (Inanaga et al., 1978). However, the improve¬ 
ments in symptoms after TRH administration are not complete, usually 
being about 50% less than full remission, and are temporary. Therefore 
TRH is not considered a useful psychotropic medication (Loosen and 
Prange, 1980). Behavioral effects induced by TRH in animals have been 
more extensively studied, and seem to be related to central effects on 
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several neurotransmitter pathways, including cholinergic and dopaminer¬ 
gic. In mice, TRH administration causes various stereotyped movements, 
which can be potentiated or blocked by various compounds known to be 
agonists or antagonists of acetylcholine or DA (Ushijima et al., 1984). 
In addition, naloxone was found to block some behavioral responses to 
TRH in rats, indicating that endorphin pathways as well as the catecho- 
laminergic ones may be affected by TRH (Lin et al., 1983). 
2) The effects of TRH administration on some other hormones 
a) T3 and T4 After administration of TRH, there is a rise in serum 
T^ and T^ which occurs somewhat later than the rise in TSH. The peak in 
the T^ rise occurs at about 60 minutes after the TRH dose, and T^ rises 
more slowly, peaking three hours or more after the TRH dose (Loosen et 
al., 1982). 
b) Prolactin. There is a significant rise in serum PRL after TRH is 
given, with a greater response seen in females than in males. Certain 
subjects are found to have a PRL response to TRH which is less than 
expected, or blunted, but this has not been found to correlate with TSH 
blunting (Loosen and Prange, 1982). 
c) Growth hormone. There is usually little change in GH after a dose 
of TRH. However GH has been found to rise after TRH infusion in certain 
conditions, which has been called a paradoxical response, as already 
mentioned. This has been reported to occur in conditions such as 
acromegaly and chronic renal failure (Reichlin, 1981), anorexia nervosa 
(Gold et al., 1981), schizophrenia (Weizman et al., 1982), and liver 
cirrhosis (Salerno et al., 1982). 
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3) Factors which affect the TRH test 
a) Age. Studies have indicated that there is negative correlation 
between age and TSH response to TRH in males, but not in females (Jack- 
son, 1982). Snyder and Utiger (1972) looked at the TRH test in normal 
males of different age groups and found the mean ATSH in the 20-39 
year old age group was 14.3 yg/ml. There was a steady and significant 
decrease in this value in the older age groups. It fell to 9.1 in the 
40-59 year olds, and to 6.1 in 60-79 year olds. The age effect may be 
an important factor in studies of the TRH test in psychiatric patients, 
since some researchers define a ATSH of less than 7 yg/ml as blunted, 
max 
while Snyder found the mean value in patients over 60 was 6.1 yg/ml. A 
recent study, however, found no significant effect of age on TSH 
response to TRH in depressed patients (Wahby et al., 1985b). The pres¬ 
ent study did not include any subjects or controls over 60 years old, 
and controls were similar to patients with respect to age. 
b) Sex. There is some disagreement in the literature as to whether 
there is a difference in TRH test results between the sexes, however 
most studies found a significantly greater TSH response in females (Hai- 
gler et al., 1971; Noel et al., 1974; Scanlon et al., 1978). The study 
by Scanlon et al. found that the response to TRH may be related to the 
phase of the menstrual cycle, with the greatest TSH rise in females 
occuring in the preovulatory stage. Most studies reporting no differ¬ 
ence based on sex did find a tendancy toward a greater response in 
females which did not reach statistical significance given the number of 
subjects tested. A study by Snyder and Utiger (1972) reported a mean 
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TSH response of 14.3 yg/ml in males and 16.8 yg/ral in females, but this 
difference was not significant. Loosen et al. (1982) reported a mean 
ATSH of 18.5 yg/ml in females and 13.7 yg/ml in males, which also did 
max 
not reach significance. Thus the data on the whole support the exis¬ 
tence of a greater response to TRH in women. Sex hormones are probably 
the major factor behind the observed differences, since they are known 
to affect the HPT axis, and the synthetic estrogens and progestins in 
oral contraceptives are known to increase TSH response in women (Reich- 
lin, 1981). The effects of sex and contraceptive use are important fac¬ 
tors that have not been controlled for in some of the studies on the TRH 
test in psychiatric patients. The present study was limited to males in 
order to avoid this possible confounding variable. 
c) Circadian rhythms and sleep. The normal secretion of TSH follows a 
circadian rhythm, with normal fluctuations every 1-2 hours, possibly 
indicating a pulsatile secretion (Parker et al., 1976). The TSH level 
normally rises in the evening, reaching its peak daily value shortly 
before the onset of sleep, and there is some evidence that sleep may 
have an inhibitory influence on TSH secretion, since the daily peak is 
delayed in sleep-deprived subjects. Since sleep/wake cycles are known 
to be disturbed in some psychiatric patients, they may also have dis¬ 
turbed circadian rhythms of TSH secretion, which may affect their 
response to the TRH test. Most studies of the TRH test in psychiatric 
patients have tried to control for this variable as much as possible by 
doing all TRH testing at the same time of day. 
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d) Nutritional state. Acute starvation is known to decrease baseline 
TSH levels as well as TSH response to TRH (Pimstone et al., 1973; Croxon 
et al., 1977; Rojdmark, 1983). It has been speculated that this 
response may be adaptive in conserving energy, but little is known about 
whether this is actually the case and what the mechanism of the observed 
response is. There do not seem to be characteristic changes in the TRH 
test in patients with anorexia nervosa, except possibly a delayed 
ATSH , as discussed in a later section. Subjects in the present study 
max 
were given the TRH test on the morning after an overnight fast in an 
attempt to minimize their differences in nutritional status. 
e) Height and weight. There have been no effects on the TRH test 
attributed to differences in height or weight (Snyder and Utiger, 1972). 
f) Thyroid hormones. It is well-known that the level of serum thy¬ 
roid hormones is one of the most important determinants of baseline TSH 
release as well as TRH induced TSH release (Reichlin, 1981). Hyperthy¬ 
roid subjects have blunted TSH responses to TRH, therefore it is impor¬ 
tant to determine the baseline thyroid hormone status of subjects in TRH 
stimulation studies. Most studies have included only subjects found to 
be euthyroid clinically as well as by laboratory determination of thy¬ 
roid hormone levels. 
In recent years it has become evident that a number of thyroid hor¬ 
mone abnormalities can be seen in patients who are clinically euthyroid 
but have some serious physical or psychiatric disorder. There are sev¬ 
eral excellent reviews of these findings (Borst et al., 1983; Chopra et 
al., 1983; Larsen, 1984). Some have called this the "euthyroid sick 
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syndrome", but actually there are a variety of abnormal findings in dif¬ 
ferent patients, so the changes in thyroid hormones found in non-thyroi- 
dal disorders does not seem to be part of a single syndrome. 
Several findings are consistently seen however. One is a decreased 
peripheral conversion of to due to inhibition of iodothyronine 
5'-deiodinase in liver and kidney. This reaction is catalyzed by the 
same enzyme which catalyzes the breakdown of a major fraction of reverse 
triiodothyronine (rT^), so as a result serum is usually low and serum 
rT^ is high. The low T^ would normally be expected to stimulate TSH by 
reduced feedback inhibition. However, TSH is usually found to be normal 
or low in these patients, and TSH response to TRH testing may also be 
normal or reduced. This is thought to be due to the fact that a second 
type of iodothyronine 5'-deiodinase found in pituitary cells is appar¬ 
ently not inhibited under the same conditions as the peripheral enzyme, 
so circulating T^ can be converted to T^ within the pituitary and con¬ 
tinue to provide negative feedback on TSH release despite greatly 
decreased peripheral T^ levels. Another prevalent finding is altered 
binding of thyroid hormones, especially T^, to plasma proteins due to 
interference by an inhibitory protein. This leads to problems with cer¬ 
tain diagnostic tests, especially the FT^I, since this value is actually 
estimated from radioactive T^ uptake and assumes certain relationships 
between thyroid hormone binding protein concentrations as well as their 
relative affinities for T^ and T^. Because some ill patients have 
alterations in binding affinities due to the circulating inhibitory fac¬ 
tor, and decreased binding protein concentrations due to decreased 
hepatic synthesis, assumptions made in calculating the FT^I do not hold 
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true, and the FT^I will not accurately reflect free levels. The 
actual levels of FT^ and TT^ found in the patients with the other abnor¬ 
malities mentioned may be high, low, or normal in different patients. 
Since there may be disturbances in to conversion, thyroid hormone 
production, and binding to serum proteins, it is easy to postulate that 
the various levels seen may depend on which of these abnormalities is 
predominant. 
g) Repeated TRH administration. It has been shown that repeated 
administration of TRH results in a reduced TSH response to subsequent 
testing (Snyder and Utiger, 1983). The effect of a single dose of TRH 
can still be observed for up to one week after administration (Winokur 
et al., 1984). This factor may be very important in interpreting some 
studies which have looked at effects of various treatments on the TRH 
test in psychiatric patients, since many have repeated the test at vari¬ 
ous time intervals. For example, in the study by Langer et al. (1983) 
subjects were given TRH tests weekly for eight weeks. 
h) Dopamine and dopamine agonists. The administration of DA prior to 
the TSH stimulation test results in a decreased TSH response (Besses, 
1975; Scanlon et al., 1979). Acute infusion of DA during treatment of 
shock is also reported to lower baseline TSH (Kaptein et al., 1980). 
However, chronic treatment with 1-dopa is not reported to affect base¬ 
line levels of TSH or T^, but does result in a decreased response to the 
TRH test (Spaulding et al., 1972). Other DA-agonists including bromo¬ 
criptine and apomorphine are also reported to inhibit TRH-induced TSH 
secretion (Foord et al., 1984). 
22 

i) DA antagonists. As might be expected, DA antagonists seem to have 
the opposite effect on TRH-induced TSH secretion as DA agonists; specif¬ 
ically, antagonists have been found to increase the TSH response. These 
agonists include metoclopramide, sulpiride and domperidone. Scanlon et 
al. (1979) gave 20 healthy subjects 10 mg of metoclopramide an hour 
before a TRH test and found a significantly greater TSH response, com¬ 
pared to a TRH test done a week earlier. The increase seen was greater 
in females than in males. Another study (Wenzel and Doring, 1982) found 
a trend toward an increased TSH response after administration of domper¬ 
idone although it was not significant in the 14 subjects tested. This 
is despite the fact that domperidone does not cross the blood-brain bar¬ 
rier and implies that it exerts its effect directly at the level of the 
pituitary, which lies outside the barrier, rather than centrally. 
Although metoclopramide increases TSH response in normal controls, it 
has not been found to reverse the blunted responses seen in acute star¬ 
vation (Rojdmark, 1983). 
j) Antipsychotics. Drugs with antipsychotic activity have been found 
to be DA antagonists which act by blocking DA receptors. Given the 
findings of increased TSH response to TRH seen after the administration 
of the DA antagonists mentioned above, it might be predicted that antip¬ 
sychotics would also cause an increased TSH response. The experimental 
findings on the affects of antipsychotics in normal controls do tend to 
show an increased TSH response to TRH. However, there have been few 
such studies in humans, partly because it is difficult to justify them 
on ethical grounds given the known side effects of the drugs (tardive 
dyskinesia, acute dystonic reactions, parkinsonianism, anticholinergic 
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effects, and so on; see section on side effects below). Those studies 
that have been done looked at the acute effects of antipsychotics after 
one or two doses, rather than during long-term treatment. 
Kirkegaard et al. (1977) examined the effect of chlorpromazine (CPZ) 
on the TRH test in 11 healthy controls. A baseline TRH test was done on 
no medications and then one week later the TRH test was done again while 
CPZ was being infused. The TSH response to TRH was significantly higher 
with the drug, as might be expected, based on the known effects of other 
DA antagonists. In another study (Kirkegaard et al., 1978), 10 healthy 
controls were given two doses of haloperidol 5 mg with biperiden 2 mg, 
at 12 and 4 hours before the TRH test. Again, the controls showed an 
increased TSH response. These controls also had had a baseline TRH test 
done one week earlier, and as Winokur et al. (1984) demonstrated, 
repeated TRH testing at intervals of up to a week tends to reduce the 
TSH response, so the finding of an increased response may indicate that 
the effect of the drug was greater than the effect of repeated testing. 
One additional study was done giving antipsychotics to non-psychotic 
subjects but is difficult to interpret, since the subject population 
consisted of hospitalized patients with a variety of diagnoses including 
general paresis, vertigo, tremors, acromegaly, cerebral thrombosis, men¬ 
tal retardation and others (Lamberg et al., 1977). The authors report a 
decreased TSH response to TRH after one dose of 50 mg CPZ, but this TRH 
test was done one day after a baseline TRH test had been done without 
medication, so a diminished response could have been expected on the 
second day even without the CPZ due to the effect of repeated testing 
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already mentioned. Next, eight subjects from subject the pool described 
above, who had been previously drug-free, were treated with 50 mg/day of 
CPZ for eight days. A TRH test done after the eight days of treatment 
again revealed a significantly lower mean ATSH than that of 25 normal 
controls as had been reported in a previous paper. An additional group 
of 11 previously drug-free patients was tested both before and after 
eight days of treatment with 50 mg/day of CPZ. Although the mean 
ATSH decreased from 9.4 yU/ral to 7.5 pU/ml after treatment, the dif- 
max 
ference between these two means was not significant. The mean ATSH 
max 
after treatment, but not before, was significantly lower than that of 
the normal controls. The authors also treated a group of idiopathic 
mentally-retarded patients with 100-700 mg/day of thioridazine for over 
a year (although it was not clear why these patients were being treated 
with thioridazine) and performed a TRH test on these patients sometime 
during therapy. They found the mean ATSHmax to be significantly lower 
than that reported for the normal controls. 
Thus the studies by Kirkegaard's group suggest that acute administra¬ 
tion of antipsychotics may increase TSH response, as would be predicted 
theoretically. The studies by Lamberg's group report the opposite find¬ 
ing, although the subjects studied had a variety of medical illnesses 
which may have affected the results, and repeated testing may have 
reduced the TSH response. Thus, although short-term administration of 
antipsychotics appears to increase the TSH response to TRH, the effects 
of more prolonged antipsychotic administration on normal controls is not 
known. The above discussion reviewed the work done on healthy controls. 
Studies involving psychiatric patients are reviewed in a later section. 
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k) Amphetamines. The action of amphetamines is thought to be due to 
their stimulatory effect on central adrenergic and dopaminergic activ¬ 
ity. Some researchers have reported them to cause a decreased TSH 
response to TRH, as might be predicted from their central effects 
(Extein et al., 1982), while others reported a normal TSH response to 
TRH in amphetamine abusers although they were found to have elevated 
thyroid hormone levels and normal TSH levels (Morley et al., 1980). 
l) Antidepressants. Treatment with antidepressants is not thought to 
affect the TRH test. They are not responsible for the blunted response 
to TRH often seen in depression, because blunting has been observed even 
in depressed patients who had no prior antidepressant intake (Loosen and 
Prange 1982). 
m) Iodide. The HPT axis is affected by iodine ingestion. At high 
levels, iodine has an inhibitory effect on T^ and T^. TSH is also found 
to be slightly decreased, and the TSH response to TRH is somewhat dimin¬ 
ished (Ingbar and Woeber, 1981). 
n) Serum calcium. Since it is known that calcium fluxes are important 
in the mechanism of TRH-induced stimulation of TSH secretion by the thy- 
rotrope, the serum calcium level might be expected to influence the TRH 
test. A study by Hiramatsu et al. (1983) showed that patients with ele¬ 
vated serum calcium due to hyperparathyroidism had a diminished TSH 
response to TRH. Conversely, patients with low serum calcium due to 
hypoparathyroidism showed an increased TSH response. The results of the 
study are consistent with those of Dudczak et al. (1983), who found a 
diminished TSH response to TRH in normal subjects given an infusion of 
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calcium acutely, while normal subjects given EDTA to lower serum acutely 
were found to have an increased TSH response to TRH. Veldhuis et al. 
(1984) reported similar findings. These studies in humans agree with 
previously described findings in rats (Sowers et al., 1980). The pres¬ 
ent study included a test of serum chemistries (SMA-18), and any sub¬ 
jects exibiting abnormal serum calcium levels would have been excluded. 
Since TRH activation of the pituitary thyrotrope is thought to be 
mediated by calcium fluxes, it might be expected that calcium channel 
blockers would have some effect on TSH response to TRH. In a study by 
Struthers et al. (1983), verapamil was found to inhibit TSH response to 
TRH in normal subjects, but nifedipine did not. It was also found that 
nifedipine did not inhibit TRH-induced protein phosphorylation in rat 
pituitary cells. 
O) Glucocorticoids. The administration of glucocorticoids in pharmaco¬ 
logical doses is known to decrease the TSH response to TRH and blunting 
is seen in untreated patients with Cushing's disease (Otsuki et al., 
1973). The mechanism is not known, but glucocorticoids are known to 
have effects at several points on the HPT axis. For example, they 
affect serum binding proteins and extrathyroidal conversion of T^ to T^. 
There may also be direct effects on the pituitary, since TSH has been 
found to be increased in Addison's disease in the absence of hypthyroi- 
dism (Topliss et al., 1980). Since the administration of glucocorti¬ 
coids is known to decrease the TSH response to TRH, it might be expected 
that high cortisol levels caused by acute stress would affect the TRH 
test. There is some evidence that this is in fact the case. 
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p) Neurotensin. The TSH response to TRH has been reported to be 
diminished after administration of neurotensin (Nemeroff et al., 1980). 
q) Somatostatin. The administration of somatostatin has been found by 
several research groups to decrease the TSH response to TRH (Vale et 
al., 1973; Azukizawa et al., 1976). 
r) Growth hormone. An increased level of GH has been reported to 
cause a diminished TSH response to TRH (Loosen et al., 1982). 
S) Certain clinical conditions. Patients with chronic renal failure 
have been shown to have a diminished TSH response to TRH, but the mecha¬ 
nism behind the finding is not known (Czernichow et al., 1976). Also, 
persons with Klinefelter's syndrome have been shown to exhibit dimin¬ 
ished TSH response to TRH by an unknown mechanism (Smals et al., 1977). 
D. The TRH Test in Some Psychiatric Illnesses 
1) Overview 
Responses to the TRH test a variety of psychiatric disorders have been 
examined following the observation by Prange et al. (1972) that a high 
proportion of euthyroid depressed patients showed a blunted response. 
In addition to whatever neuroendocrine changes that may result from a 
psychiatric disorder, there may also be changes resulting from the 
effects of hospitalization itself or the high stress levels accompanying 
a psychiatric disorder. The euthyroid sick syndrome (ESS) seen in some 
hospitalized patients with psychiatric as well as physical disorders has 
already been described. Several studies have examined thyroid parame¬ 
ters in psychiatric patients on admission. Cohen and Swigar (1979) 
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tested 480 patients being admitted for acute psychiatric problems and 
found 9% to have an elevated FT^I and 9% to have an abnormally low FT^I. 
In 150 similar patients, Levy et al. (1981) found a 7% incidence of 
abnormalities which they report as suggestive of ESS on initial testing, 
and on serial testing found that 27% showed ESS at some point during 
hospitalization. The abnormalities were transient in most cases. 
Another study (Spratt et al., 1982) found that of 645 acute psychiatric 
admissions, 34% of the patients showed a high serum at some point, 
and 18% showed a high FT^I. Of these patients, 258 were schizophrenic, 
and they showed a 41% incidence of increased serum and a 21% inci¬ 
dence of increased FT^I. Again, most of these abnormalities were found 
to be transient. A TRH test was done on 10 of the schizophrenics who 
had high levels, and five of the 10 showed a blunted response. How¬ 
ever, since high levels are known to cause a blunted response, the 
significance of this finding is not clear. A review of some of the 
studies looking at the TRH test in various psychiatric disorders fol¬ 
lows . 
2) Major depressive disorder 
Since the high proportion of blunted responses to TRH in depressed 
patients was first described by Prange et al. in 1972, many further 
studies have been done replicating this finding. Loosen and Prange 
(1982) reviewed 41 studies involving 917 patients. Most studies tended 
to support the finding that roughly 25% of depressed patients show a 
blunted response. 
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Much research has been directed toward finding an explanation as to 
what distinguishes those depressed patients who are blunters, why some 
but not all blunters stop blunting upon recovery, and what the mechanism 
of the response is. There are still no conclusive answers to these 
questions. Blunted responses are seen in depressed patients with normal 
thyroid indices on no medications, so the mechanism responsible is prob¬ 
ably not a disturbance in thyroid hormones which is often seen in hospi¬ 
talized patients, nor is it due to medications. Although some research¬ 
ers report a higher incidence of blunting in unipolar as opposed to 
bipolar depression (Kirstein et al., 1981), this finding has not been 
widely confirmed. In addition, the reason that some patients continue 
to blunt after recovery, while others return to a normal response has 
not been elucidated. Loosen and Prange (1982) suggest that blunting may 
sometimes be a state marker and sometimes a trait marker, and that at 
the present time it is not possible to predict for a given patient if a 
blunted response will continue upon recovery. 
There have been several attempts to correlate TRH test results with 
outcome. Although controversy still exists in this area (Loosen and 
Prange, 1982), some studies have shown a better outcome in those 
patients who initially had a blunted response (Targum et al., 1983). 
The mechanism behind the observed blunting is unclear. Loosen and 
Prange (1982) have suggested several possibilities, based on some of the 
known actions of neurotransmitters: 1. Reduced serotonin levels could 
lead to increased TRH release, since serotonin is thought to inhibit 
TRH. The increased TRH would then cause a down-regulation of the thyro- 
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tropes' responsiveness to TRH. This possibility is compatible with the 
biogenic amine hypothesis of depression which states that a reduction in 
serotonergic activity may be present in depression. 2. Increased NE 
levels could also lead to increased TRH release, since NE is known to 
stimulate TRH release. Although biogenic amine hypotheses of depression 
have generally postulated a decreased level of NE rather than increased, 
Loosen and Prange note that some findings may be compatible with 
increased NE levels in depression. 3. Although usually not considered 
to play a central role in biogenic amine hypotheses of depression, an 
excess of dopaminergic activity could lead to a blunted response by 
inhibiting TSH directly (Besses et al., 1975). Another possible mecha¬ 
nism for blunting suggested by Winokur et al. (1984) is an overall 
increase in TRH secretion in depression, which may have central behav¬ 
ioral effects as well as effects on the HPT axis. In support of this 
hypothesis the authors cite a study (Kirkegaard et al., 1979) which 
found higher TRH levels in the CSF of depressed patients compared to 
neurologic patients. 
The secretion of prolactin, like TSH, is influenced by both DA and 
TRH. Therefore, if the mechanisms suggested above are true, a blunted 
response of prolactin as well as TSH to the infusion of TRH might be 
expected in depression. Loosen and Prange (1982) noted that in 11 stud¬ 
ies looking at both prolactin and TSH responses to TRH, some prolactin 
blunting was seen, but it could only be partially correlated with TSH 
blunting. 
3) Manic disorder 
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The finding of a blunted response to TRH infusion in manics is less 
well-established than the finding in depressed patients, but it does 
appear that manics show a higher proportion of blunted responses than 
the general population. In a review of five studies, Loosen and Prange 
(1982) report that four of them found either a slightly lower mean 
ATSHmax in manics, or a large proportion of blunted responses. 
One factor that must be controlled for in studies on manic patients 
is whether they have been treated with lithium recently, since lithium 
is known to interfere with thyroid hormones, occasionally causing overt 
hypothyroidism. An exaggerated response to TRH is found in patients 
with primary hypothyroidism, and this is also what is found after 
lithium administration. 
Another factor which may influence TRH testing results in manic 
patients is the effect of sleep/wake cycles. As discussed in an earlier 
section, TSH secretion is known to have a circadian rhythm, reaching a 
peak level just before the onset of sleep, and there is some evidence 
that sleep may exert an inhibitory influence on TSH secretion (Parker et 
al., 1976). Since manic patients have grossly disturbed sleep/wake 
cycles, it might be expected that this would influence their response to 
TRH in some way, but thus far the exact relationship has not been worked 
out. 
4) Alcoholism 
Several studies have found alcoholics to have a higher proportion of 
blunting in response to TRH than normal controls (Loosen et al., 1979, 
1983; Gold et al., 1981). Blunting was found both during and after 
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acute withdrawal, and after long-term abstinence. In the later study by 
Loosen's group, 29 male alcoholics who had been abstinent for more than 
two years were tested and a 31% incidence of blunting was found. The 
authors state that the findings could not be explained on the basis of 
age, effects of withdrawal, liver disease or other physical disorders. 
They concluded that blunting may sometimes be a state marker in alcoho¬ 
lism, and sometimes a trait marker, which is similar to what they found 
in depressed patients. 
The study also showed the alcoholic group to have a high incidence of 
thyroid abnormalities characteristic of the euthyroid sick syndrome, 
including reduced mean levels of T^ and TSH, normal T^, increased rT^ 
and decreased binding capacity. However there was no clear correlation 
between abnormal levels of TSH or thyroid hormones and whether or not an 
individual showed a blunted response. The authors did find a signifi¬ 
cant positive correlation between basal T. and ATSH in blunters, but 4 max 
not in non-blunters, which could not be explained. 
The relationship between alcoholism and depression is interesting. 
It has been observed that many alcoholics have an underlying affective 
disorder, and genetic studies have found that depression and alcoholism 
often run in the same families. Whether there is a genetic link between 
the disorders has not been determined, but finding similarities in TRH 
test responses in the two groups may provide some further support for 
this hypothesis. 
5) Anorexia nervosa 
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In a series of six studies on the TRH test in anorexic patients reviewed 
by Loosen and Prange (1982), all but one study showed normal responses 
to TRH. However, those studies which commented on the timing of the TSH 
response noted that there tended to be a delayed recovery phase. Exami¬ 
nation of the GH response to TRH by one group (Gold et al., 1981) found 
a paradoxically increased GH response in all of five anorexics tested, 
while none showed an abnormal TSH response. 
6) Borderline personality disorder 
Most researchers have stated that the response of borderline patients to 
TRH does not differ from that of controls. In fact some researchers 
examining the TRH test in psychiatric patients used borderline subjects 
as their controls (Extein et al., 1980, 1982). Another group gave the 
TRH test to a group of 24 female borderline patients who were depressed 
and found nine of the 24 had blunted responses (Sternbach et al., 
1983a), which the authors suggest is an indication that when borderline 
patients become depressed they may exibit neuroendocrine abnormalities 
similar to depressed patients without an underlying personality disor¬ 
der . 
7) Schizoaffective disorder 
There has been less research done on schizoaffective disorder than on 
many other psychiatric disorders. It is not clear whether schizoaffec¬ 
tive disorder is a distinct entity or represents a combination of sev¬ 
eral subgroups of psychiatric illnesses classified together because of 
imprecision in diagnostic capabilities. 
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In any case, several studies have been done on the TRH test in schi- 
zoaffectives, and have been reviewed by Meltzer et al. (1984). Three of 
4 studies examined found a fairly high percentage of blunting, from 3 
out of 15 patients (Gold et al., 1981), to 5 out of 13 (Meltzer, unpub¬ 
lished data in Meltzer et al., 1984), to 5 out of 10 (Targum, 1983). 
The fourth study (Loosen and Prange, 1980) found none of the patients 
had a blunted response. It is interesting that the schizoaffective 
patients were divided into manic or depressed type in the Gold study, 
and three out of ten of the manic types blunted while none of the five 
depressed types blunted. Also, Targum's study must be interpreted cau¬ 
tiously, since the patients studied had suffered a first psychotic break 
and did not all strictly meet the criteria for schizoaffective disorder. 
The author notes that "many of these patients could be considered to 
have 'probable' affective disorder on the basis of their full remission 
and psychopharmacological responses." The methodologies of these stud¬ 
ies varied, which also may explain some of the differences observed. 
Since all of the studies except Meltzer's examined schizophrenic as well 
as schizoaffective patients, a more detailed discussion of their method¬ 
ology and findings follows. In summary, there seems to be some evidence 
that schizoaffective patients may have a slightly higher rate of blunted 
responses than controls. The exact percentage of blunting has not been 
established and may vary in the different subtypes of the disorder. 
8) The TRH test in schizophrenics 
a) Baseline hormonal parameters. Although there has been some 
research on possible neuroendocrine changes in schizophrenia, no consis- 
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tent findings have emerged. In light of the DA hypothesis of schi¬ 
zophrenia, it would not be surprising to find some neuroendocrine abnor¬ 
malities. Since DA is known to inhibit the TSH response to TRH, the 
increased DA activity which is postulated to occur in schizophrenia 
might be expected to have an effect on the HPT axis. Antipsychotics 
also affect DA activity, and although there is some disagreement about 
their effects on the HPT axis (see later section), there is no disagree¬ 
ment on their stimulatory effects on pituitary PRL-secretion, so they do 
have at least one well-characterized effect on pituitary function. Thus 
studies on neuroendocrine effects of antipsychotics in schizophrenics 
have tried to examine possible effects of medication and illness alone 
before looking at schizophrenics while on medication. 
There have been several reports of abnormalities in baseline thyroid 
function tests in schizophrenics, with some disagreement over the direc¬ 
tion of the abnormalities. The studies discussed at the beginning of 
this section did find a high percentage of transient thyroid abnormali¬ 
ties in psychiatric patients as a group, but most did not examine diag¬ 
nostic categories separately. Prange et al. (1979) found a significanly 
lower T^ level in 17 schizophrenic patients on no medications, as com¬ 
pared to matched controls, as well as an increased FT^I. The authors 
also noted that the increased FT^I observed could probably be accounted 
for by the fact that the patients had decreased T^ binding capacity but 
normal TT. levels, and this could lead to an increased FT,I. The schiz- 4 4 
ophrenics also had slightly higher baseline TSH levels, but the differ¬ 
ence was not significant. 
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A study of the baseline thryroid hormone levels of 258 schizophrenic 
patients at the time of admission showed 41% with elevated serum and 
21% with elevated FT^I (Spratt et al., 1982). 
Schizophrenics have been reported to be susceptible to the "euthyroid 
sick syndrome" which, as already discussed, can occur in a variety of 
non-thyroidal illnesses and effects thyroid function tests in a charac¬ 
teristic manner (Larsen, 1984; Borst, 1983; Chopra, 1983). The main 
findings in ESS include a decreased peripheral conversion of to T^, 
increased rT^, normal or decreased TSH, and decreased thyroid binding 
globulin. may be increased, decreased, or normal. The FT^I is mis¬ 
leading in this syndrome because it uses a measure of T^ uptake to esti¬ 
mate T^. This is valid when the relative binding of T^ and T^ to serum 
proteins is fixed, but in ESS the proportions of binding proteins may 
change, and because these proteins have different affinities for T^ com¬ 
pared to T^, serum binding characteristics change. 
Studies on PRL in schizophrenics have shown normal baseline and TRH 
stimulated levels of PRL (Loosen and Prange, 1980). Prolactin was also 
reported to be normal on repeated longitudinal sampling during the 
course of the illness. In addition, these authors report no change in 
the normal rise of PRL during sleep in schizophrenics. There is one 
recent report of a decreased prolactin level in ten drug free acute 
schizophrenic males (Rao et al., 1984). 
b) The TRH test in unmedicated schizophrenics. There is less disa¬ 
greement about the TRH test in schizophrenics than about their baseline 
thyroid function tests. Most studies have shown no difference between 
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controls and schizophrenics on this test. There was no significant dif¬ 
ference in the ATSH between 17 schizophrenics and 23 normal controls 
max 
in a study by Loosen and Prange (1980). None of the schizophrenics or 
controls showed a blunted (<5 yU/ral) response. The same 17 schizophren¬ 
ics had previously been compared to 17 normal controls in another paper 
(Prange et al., 1979) and no significant difference in their baseline 
TSH or ATSH was found, 
max 
Another study (Loosen et al., 1977), found no significant difference 
between the group ATSHmax means between 9 schizophrenics and 40 healthy 
controls, although the mean response was slightly higher in the schizo¬ 
phrenic group. 
Extein et al. (1980) also found no significant difference in the 
group means of ATSH between five schizophrenics and five controls. 
The controls used in this study, however, were in fact patients with 
various personality disorders. 
Targum (1983) reported on the TRH test results of 17 unmedicated 
patients with schizophreniform disorder, who were hospitalized for the 
first time. Five of the patients showed a blunted response (<7 yg) ini¬ 
tially. These patients were followed for six months, and at that time 
seven of them were not improved and their diagnosis changed to schi¬ 
zophrenia. None of the patients who were later diagnosed as schizo¬ 
phrenic had a blunted response on admission. Many of the remaining 
patients had responded to antidepressant or lithium therapy, and the 
authors conclude that they may have had a variant of affective disorder, 
but on initial presentation it would have been impossible to tell if 
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their eventual diagnosis would be schizophrenia or one of the affective 
disorders. 
Another study (Gold et al., 1981) found that none of 14 schizophrenic 
patients showed a blunted response to TRH. However, when they tested 
schizoaffective patients they found blunting in 6 of 13 patients classi¬ 
fied as schizoaffective, manic type, while none of five classified as 
depressed type showed blunting. 
A group of nine acutely psychotic patients who had been previously 
drug-free were tested by Naber et al. (1980b). Normal baseline and 
stimulated TSH levels were noted. 
Only one study was found which presented data disagreeing with those 
discussed above (Langer et al., 1983). Twenty-one female patients cat¬ 
egorized as "paranoid hallucinatory" were studied. This group was com¬ 
prised of patients classified by RDC as manic, schizophrenic, or or 
schizoaffective. Of the 11 who were schizophrenic, four were found to 
have a blunted response. These patients had been drug free (except for 
some interim benzodiazepines) for two to three days before the test. 
The mean ATSH for this group was also reported to be significantly 
lower than normal controls, although the actual values were not given. 
c) The TRH test in schizophrenics on antipsychotics. Very few studies 
exist which have looked at the TRH test in schizophrenics before and 
after taking antipsychotic medications. Most studies have looked at TRH 
test results in groups of patients after long-term antipsychotic therapy 
and found no difference from normal values. Those studies that have 
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been done show different results. One before and after study found no 
changes on TRH test results, one found a decreased ATSH on medica- 
m 3.x 
tions, and one apparently found a decreased level of blunting while on 
antipsychotics. 
In a study comparing 5 patients with reactive paranoid psychosis and 
60 normal controls, Kirkegaard et al. (1978) found that their ATSH^ 
did not differ significantly. Three of the five patients had been on 
antipsychotics, but they were not specifically compared to the two who 
were not. 
Extein studied 30 undifferentiated schizophrenics, all except 5 of 
whom were on antipsychotic medication. An analysis of this group as a 
whole showed no significant difference in baseline TSH from 60 healthy 
controls. However, the ATSH^^ of the schizophrenic group was lower 
than that of the controls, and the difference between the means of the 
natural log of ATSH was significant. 
The TRH test response both before and after antipsychotic medication 
was examined in the study by Langer et al. (1983), of 21 paranoid-hallu¬ 
cinatory females. This group contained 11 schizophrenics, who had been 
drug-free for two to three days prior to the first TRH test (possibly an 
inadequate washout period). As noted above, the ATSH of this group 
while off medications was reported to be significantly lower than con¬ 
trols, the only study with such a finding, although the actual means 
were not given. The patients were then begun on treatment with haloper- 
idol, 10-30 mg, and a TRH test was done weekly for 8 weeks. Given the 
findings of Winokur et al. (1984) that weekly TRH testing in and of 
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itself can lead to a blunted response, the patients in Langer's study 
may have been expected to show an even more blunted response on later 
testing. This was not the case however. Although actual means are not 
given, the authors report that of the seven patients who exhibited 
blunted TSH responses off medications (four of whom were schizophrenic), 
only two continued to have a blunted response. The diagnoses of these 
two were not indicated, so it is not possible to follow what happened to 
the schizophrenic patients. However, of the four schizophrenic patients 
who had blunted responses originally, between zero and two of them (the 
exact number is not given) had a large enough increase in ATSH^ to be 
considered no longer blunted. Presumably, none of the schizophrenics 
who had not blunted off medications became blunters, since the diagnoses 
of the patients were not clearly specified in the results. In addition, 
given the possible confounding influences of medications prior to the 
study, as well as weekly TRH infusions, it is difficult to draw firm 
conclusions about this study. 
Naber et al. (1980c) studied nine acutely psychotic patients who had 
been drug-free prior to the first TRH test for at least three weeks, 
although some had previously been on antipsychotics. These patients 
were begun on a variety of antipsychotic medications based on clini¬ 
cian's preference and clinical response. Additional TRH tests were car¬ 
ried out at two, four, and six weeks of treatment. No significant 
changes in baseline TSH or ATSH were seen. 
max 
In the same paper, the authors report on TRH test results in a group 
of 22 chronic schizophrenics who had been on long-term antipsychotic 
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therapy (mean=13 years). Again, no significant difference was seen in 
baseline TSH or ATSH . The authors did note one patient with an ele- 
max 
vated baseline TSH and two with elevated ATSH . In addition, a sig- 
max 
nificant positive correlation was found between lifetime antipsychotic 
dose and ATSH in the 12 male patients, but this correlation was not 
max 
found in females. 
It is interesting that the results of this same study are also 
reported in two other papers (Naber et al., 1980a, 1980b), which reveal 
that in fact the patients received not only 200 yg TRH in the experimen¬ 
tal infusion but also 25 yg of luteinizing hormone releasing-hormone 
(LHRH) simultaneously in order to test the LH response. Although the 
simultaneous co-administration of LHRH with TRH may not affect the 
results of the TRH test, it does affect the generalizability of the 
findings and should have been mentioned in the methods section of the 
paper. Also, the method of TRH stimulation used in this study differs 
from most studies in that only 200 yg of TRH was used, and blood was 
collected only once, at 30 minutes. 
A paper by Lamberg et al. (1977) contains a study of TRH testing of 
schizophrenics after long-term antipsychotic therapy. Results were com¬ 
pared to baseline TSH and ATSH levels found in 25 healthy controls in 
max 
a previous study. Looking at nine schizophrenics who had been on 75 to 
1000 mg/day of CPZ for more than one year, they found a significantly 
lower ATSH 
max 
d) Effects of the TRH test on other hormones. Schizophrenics given 
the TRH test have been reported to show an abnormal GH response in one 
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study (Weizman et al., 1982). Ten chronic adolescent schizophrenics 
were tested and although none showed a blunted TSH response, five of the 
ten showed a paradoxical increase in GH. This type of response has been 
reported in certain other conditions (see section on GH response to the 
TRH test). The authors also noted that four of the five patients with 
an abnormal response had a family history positive for schizophrenia 
while only one of those with a normal response had a positive family 
history. 
E. Antipsychotics 
1) Mechanisms of action 
The clinical effects of antipsychotics are thought to be due to their 
DA-receptor blocking activity, although antipsychotics also bind many 
other neurotransmitter receptors including a-adrenergic, muscarinic cho¬ 
linergic, histaminic and serotonergic (Bennett, 1983). The effects of 
antipsychotics on these other transmitter systems may be responsible for 
some of the observed side effects. 
There are two classes of DA-receptors known (Cooper et al., 1982). 
DA-1 receptors are linked to adenylate cyclase while DA-2 receptors are 
not. The relative clinical efficacy of antipsychotics correlates best 
with their affinity for DA-2 receptors. 
There are five major dopaminergic pathways in the CNS: the nigrost- 
riatal, mesolimbic, raesocortical, tuberoinfundibular and tuberohypophy- 
seal (Cooper et al., 1982). The tuberoinfundibular neurons, with cell 
bodies in the arcuate and periventricular nuclei of the hypothalamus and 
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axons terminating in the median eminence, are responsible for the major¬ 
ity of the DA reaching the adenohypophysis through the connecting portal 
system. The nigrostriatal system is involved in the extrapyramidal side 
effects observed with antipsychotics. The theraputic effects of antip- 
sychotics are thught to be mediated through their effects on the meso- 
limbic and/or mesocortical systems. 
Only two of the five major dopaminergic pathways lack DA-autorecep- 
tors, the mesocortical and tuberoinfundibular. Cooper et al. (1982) 
suggest that this lack of autoreceptors in the mesocortical system may 
account for the unique responsiveness of this system to certain drugs 
and "may explain the relative resistance of these neurons to the devel¬ 
opment of tolerance during long-term treatment with antipsychotic drugs" 
(pp. 191). The lack of autoreceptors in the tuberoinfundibular pathway 
could also account for the lack of tolerance of this system to the PRL- 
elevating effects of antipsychotics. Therefore, DA activity in the 
tuberoinfundibular neurons might be a reliable indicator of the therapu¬ 
tic effect of antipsychotics in the CNS, and measuring psychoendocrine 
correlates of this activity could provide useful clinical information. 
2) Side effects 
In addition to the endocrine effects mentioned, antipsychotics have sev¬ 
eral serious side effects including tardive dyskinesia, acute dystonic 
reactions, akathesia, parkinsonianism, orthostatic hypotension, jaund¬ 
ice, and blood dyscrasias. Also, a host of other less common side 
effects have been reported (Baldessarini, 1980). Some of these side 
effects, particularly tardive dyskinesia, are of great concern since 
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they may be irreversible. Thus it is important to use antipsychotics 
only when clinically necessary, and at the minimal dose needed to insure 
a satisfactory response. Psychoendocrine testing may therefore be 
important in predicting which patients would benefit from antipsychotics 
and which ones might be more profitably started on an antidepressant or 
lithium. 
3) Effects of antipsychotics on thyroid hormones 
As with the question of the effect of antipsychotics on the TRH stimula¬ 
tion test, studies on the effects of antipsychotics on baseline thyroid 
hormone levels are not in agreement, but in looking for a possible 
effect of antipsychotics on the TRH test, it is important to examine 
whether they have any effect on other thyroid parameters, since this 
could affect the TRH test through feedback mechanisms. 
In the 1960's it was reported that protein-bound iodine (an indirect 
measure of thyroid hormone levels now in less widespread use) was 
increased after treatment with perphenazine (Cranswick et al., 1962; 
Oltman et al., 1963). Other researchers found no change (Bennett et 
al., 1961; Ayd, 1963; Hollister et al., 1963). The controversy was 
resolved after it was found that some perphenazine in use contained an 
iodine containing compound (Hansen et al., 1967). 
Most researchers have found no changes in radioactive iodine uptake 
(another measure of thyroid function) due to antipsychotics (Bennett and 
Hamilton, 1961; Crammer and Power, 1962) although one study (Blumberg 
and Klein, 1969) found an increase. However, the diagnoses of the 
patients in this study was not specified. 
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Antipsychotics have been found to cause no change in levels of thy¬ 
roid binding globulin (TBG) in a study by Naber et al. (1980c), although 
a significant negative correlation betwee TBG level and lifetime dose of 
antipsychotics was seen. 
The levels of T^ have been reported to show no change after treatment 
with antipsychotics (Naber et al., 1980c). Similarly, T^ levels have 
been reported to be unchanged after antipsychotic intake (Hansen et al., 
1967; Brambilla et al., 1975; Kolakowska and Swigar, 1977; Naber et al., 
1980c). 
The baseline TSH levels are generally reported to be normal after 
antipsychotic treatment (Wode-Helgodt et al., 1977; Naber et al, 1980c) 
although there have been reports of decreased TSH (Collu et al., 1975) 
and one report of increased, decreased and normal TSH levels after 
treatment with antipsychotics of varying lengths of time (Lamberg et 
al., 1977), however this study had a host of methodological problems as 
previously mentioned. 
The effect of antipsychotics on the TRH stimulation test in normal 
subjects was discussed in the section on factors affecting the test. A 
number of studies have found acute administration of antipsychotics to 
increase the TSH response to TRH (Kirkegaard et al., 1977, 1978). This 
is similar to the increase observed after administration of the DA 
antagonists metoclopramide (Scanlon et al., 1979; Rojdmark, 1983) and 
domperidone (Wentzel and Doring, 1982). However, the effect of pro¬ 
longed antipsychotic administration is controversial, and as mentioned, 
various authors have found normal, increased or decreased TSH response 
to TRH administration. 
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4) Effects of antipsychotics on other hormones 
a) Prolactin. The increase in PRL resulting from antipsychotic admin¬ 
istration is well known (Baldessarini, 1980). It is thought to be a 
result of the DA-receptor blocking activity of antipsychotics, since 
pituitary lactotropes are under tonic inhibition by DA, which was found 
to be the prolactin-inhibitory factor. 
The predictable effect of antipsychotics on the PRL level has been 
suggested to have clinical usefulness as a measure of compliance with 
antipsychotic treatment (Rao et al., 1980). However, other authors have 
claimed that "tolerance" to the PRL-elevating effect of antipsychotics 
occurs (Naber et al., 1977; Brown and Laughren, 1981; Zander et al., 
1981). This is an unfortunate choice of a term since the data of all 
these authors, as well as those claiming that tolerance does not occur 
(Rubin and Hays, 1980; Kolakowska et al., 1981; Ravichandran et al., 
1984) are basically consistent. 
These studies have found that there is a large initial increase in 
PRL after acute administration of antipsychotics, but with continued 
administration over time, PRL levels drop somewhat to a stable plateau 
level which is still significantly higher than the baseline level for 
individual patients, and will quickly drop to the baseline level upon 
discontinuation of antipsychotics (Naber et al., 1979). However, 
because of large individual variation in baseline PRL levels, as well as 
the magnitude of the PRL response to antipsychotics, the mean plateau 
levels of groups of patients on antipsychotics may not be significantly 
higher than normal values, especially if a small group of patients is 
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tested (type II error). Because of large individual differences in the 
magnitude of PRL response to antipsychotics, there is extensive overlap 
between PRL levels of patients on and off medications, suggesting that 
the serum PRL level would not be a reliable indicator of antipsychotic 
compliance in an individual patient. However, since the correlations 
between antipsychotic dose and PRL level is highly significant in indi¬ 
vidual patients, and is stable over time (Rao et al., 1980), if the 
response characteristics of individuals are established, then PRL levels 
would be a reliable indicator of serum antipsychotic levels over time. 
b) Other hormones. Antipsychotics have been reported to be associ¬ 
ated with reduced levels of gonadotropins, estrogen and progestins (Bal- 
dessarini, 1980). Brown et al. (1981) reported reduced LH and testos¬ 
terone in males, and a variety of effects on gonadotropins in females 
was reported by Carter et al. (1982). 
The intake of antipsychotics has also been reported to be associated 
with reduced levels of ACTH and GH, as well as an impaired glucose tol¬ 
erance in some cases (Baldessarini, 1980). 
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IV. METHODS 
A. Overview 
This study was designed to examine the effect of antipsychotic medica¬ 
tions on the TRH stimulation test in schizophrenic and schizoaffective 
patients. The TRH test was given to 33 male subjects who were in 1 of 3 
groups of interest. One group consisted of 8 psychotic patients on no 
medications (5 schizophrenics and 3 schizoaffeetives), another consisted 
of 11 psychotic patients being treated with antipsychotic medications (6 
schizophrenics and 5 schizoaffectives) and the third group contained 14 
healthy controls. 
The study was limited to males, because of the known sex difference 
in responses to the TRH stimulation test (as discussed in the introduc¬ 
tion). Including females would have added additional variability to the 
findings. Also, since the TSH response to TRH stimulation is known to 
decline with age in males, the study was limited to males between the 
ages of 20 and 60, and age was included as a possible confounding vari¬ 
able in analyzing the results. 
The standardized TRH-stimulation test as described below was adminis¬ 
tered to all subjects in the study, and the two important dependent 
variables examined were the maximum TSH increment over baseline 
(ATSH ) and the area under the response curve of TSH over time (area 
under curve). As Wilkin et al. (1979) noted, the area under the curve 
is theoretically the best indicator of TSH response, although ATSH^^ 
values are highly correlated to it. The appearance of a typical 
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response curve is given in Appendix E. The levels of these dependent 
variables were compared among the study groups looking for any differ¬ 
ences based on medication status. In the group of patients on medica¬ 
tions, the effects of drug dosage and duration of treatment on the vari¬ 
ables of interest were also examined. The results were also analyzed 
with respect to diagnosis. 
B. Patient Selection 
The subjects in this study consisted of patients who were sequentially 
admitted to inpatient psychiatric wards of the West Haven Veterans 
Administration Medical Center (WHVAMC), who agreed to participate in the 
study, and were appropriate according to the inclusion and exclusion 
criteria below. Healthy controls were selected from volunteers 
recruited from the community. The study was done in conjunction with 
Drs. Victor Wahby, John Mason, Earl Giller, and Robert Ostroff, who con¬ 
ducted TRH tests on these and other patients as part of their larger 
ongoing psychoendocrine protocol entitled "Dexamethasone and TRH Tests 
in Schizophrenics and Schizoaffectives," which was approved by the Human 
Studies Committee of the WHVAMC. 
1) Subject inclusion criteria 
Patients included in the study were male inpatients between the ages of 
20 and 60 on one of the psychiatric wards at WHVAMC who had been diag¬ 
nosed as schizophrenic or schizoaffective and who agreed to participate 
in the study. 
The medication history of all subjects was determined, and patients 
were assigned either to the study group consisting of patients on ant ip- 
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sychotic medications or the group of patients on no psychotropic medica¬ 
tions. Eight patients were included in the unmedicated group (three 
schizoaffective, five schizophrenic) and eleven patients were assigned 
to the group taking antipsychotics (five schizoaffective, six schizo¬ 
phrenic) . 
In order to compare the relative dosages of the different medica¬ 
tions, each patient's daily dose of antipsychotic was converted to 
chlorpromazine (CPZ) equivalents using conversion factors based on the 
values give by Hollister (1970) and Davis (1974). The numbers given by 
these two authors were basically in agreement with the exception of thi¬ 
othixene, for which an intermediate value was used (see Appedix D). The 
duration of antipsychotic treatment of each patient was also determined. 
In addition, 14 healthy males with no history of psychiatric illness 
were included as healthy controls. 
2) Subject exclusion criteria 
Subjects were screened and were not included if they had any history of 
thyroid disease and also were not included unless they had a negative 
drug screen. In addition, controls had no history of psychiatric ill¬ 
ness. All patients were physically examined by Dr. Wahby and only those 
without a clinically detectable endocrine or other medical disorder, as 
well as those with normal hemograms (CBC), blood chemistries (SMA-18), 
urinalyses, and basal thyroid function tests were included. Special 
attention was given to clinical thyroid examination. A medication his¬ 
tory for all subjects was elicited, and they were not included if they 
had taken lithuim within the last four months or were presently taking 
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any other medication known to have a major effect on the TRH test (see 
Appendix B). The length of continuous treatment was determined for 
those patients on antipsychotic medications by a thorough review of 
their medical records. The value used was not the total lifetime dura¬ 
tion of antipsychotic treatment, but the length of continuous unin¬ 
terrupted treatment prior to the TRH test. The present antipsychotic 
dose was then converted to CPZ equivalents in order to be comparable 
among patients (see Appendix D for conversion factors). 
C. Clinical Assessment 
All subjects had been diagnosed according to Research Diagnostic Cri¬ 
teria (RDC) as either schizophrenic or schizoaffective. The RDC as 
described by Spitzer et al. (1977) are given in Appendix C. The diagno¬ 
ses were based on an interview conducted in the Schedule of Affective 
Disorders and Schizophrenia (SADS) format (Spitzer et al., 1978). The 
SADS interview is semi-structured in format and consists of a series of 
fairly specific questions related to psychiatric symptoms. It was 
developed as a method of systematically gathering information necessary 
to make a diagnosis according to RDC. The complete RDC diagnoses of all 
patients is given in Appendix G. 
D. The TRH Stimulation Test 
1) Procedure 
All subjects fasted overnight before the test, beginning after their 
evening meal on the day prior to the test. On the morning of the test, 
a #21 gauge intravenous needle connected to a three-way stopcock was 
inserted into an antecubital vein. Through one arm of the stopcock an 
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infusion of 0.9% normal saline was started and maintained at a slow rate 
in order to keep the needle open. The second arm of the stopcock was 
used for withdrawal of blood samples. Baseline blood samples were col¬ 
lected at 9:15 and 9:30 am (samples -15 and 0, respectively). These two 
samples were used to assess the subjects' responsiveness and accommoda¬ 
tion the the stress of the test procedure, as well as to obtain baseline 
levels of TT^, FT^, TSH and PRL. 
At 9:30 am, an i.v. bolus infusion of 500 yg of TRH (Hoechst-Roussel) 
was given over 30 seconds. Blood samples were collected at +15, 30, 45, 
60, 90, and 120 minutes after injection, considering 9:30 as zero time. 
TSH and PRL was measured in all samples. Total and free T^ was measured 
in samples +0 and +120 to ensure a normal thyroid gland response. This 
effort to ensure that the test was performed at the same time of day in 
all subjects was made in order to minimize the effect of the diurnal 
variation of TSH levels. 
Each blood sample was about 6 ml, so a total of about 60 ml of 
blood was drawn. For the duration of the test, the subject was kept in 
a comfortable room, lying in bed or sitting in a chair, under the super¬ 
vision of a physician. 
2) Measurements 
Radioimmunoassay methods were used to measure serum TT^ (Garamacoat 1251 
total T^ RIA Kit, Clinical Assays, Inc. 237 Binnery St, Cambridge MA); 
FT^ (Gammacoat 1251 Free T^ RIA Kit, Clinical Assays, Inc.); TSH (RIA 
phase RIA Reagent system, Beckman Instruments Inc. Fullerton, CA) and 
PRL (Double Antibody RIA Kit, Serona Loboratories, Serona Inc, 11 Brooks 
Drive, Braintree MA). 
53 

3) Dependent variables 
The TSH level of the serum sample at each time point tested was meas¬ 
ured. The sample with the largest TSH value was determined, and usually 
turned out to be the sample taken at +30 minutes. The baseline TSH 
level was then subtracted from the TSH level of the sample with the 
largest value. The resulting number was defined as ATSH 
The ATSH^^ value was the primary dependent variable in the study. 
The response of TSH to TRH infusion was defined as blunted if the 
ATSH was <6 yU/ml. This level was chosen since most other research- 
max 
ers giving supramaximal TRH doses define a blunted response as either <5 
yU/ml or <7 yU/ml, so <6 yU/ml was chosen as a reasonable compromise. 
See the discussion section for a more detailed explanation of the blunt¬ 
ing criterion. The values of TSH were also used to generate a response 
curve of TSH value at each time point (Appendix E). The area under the 
response curve (from the baseline TSH level) was calculated by Simpson's 
rule (Sala and Hillie, 1971), and was used as an additional dependent 
variable. This variable is theoretically the best indicator of TSH 
response to TRH (Wilkin et al., 1979) but is often not used because it 
requires several samples, is cumbersome to calculate, and has been shown 
to be highly correlated to the other dependent variables such as ATSH 
and ATSH at +30 minutes, as discussed in the introduction. Similarly, 
the baseline prolactin level was subtracted from the serial values of 
prolactin obtained after TRH stimulation to generate APRL values. The 
largest such value seen was defined as APRL max. 
E. Data Analysis 
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Differences in demographic variables, baseline hormone levels, and meas¬ 
ures of TSH response to TRH among the three groups in the study (con¬ 
trols, patients on no medications and patients on antipsychotics) were 
examined using Student's t-test to find any significant differences 
between each group and the other two. Pearson's correlation coeffi¬ 
cients for each study group were calculated to examine the correlations 
between demographic variables and baseline hormone levels, between base¬ 
line hormone levels and TSH responses, and between the two measurements 
of the dependent variables used (ATSH and Area under curve). 
max 
The group of patients on medication were then examined with respect 
to the possible effects of antipsychotic dosage and duration of treat¬ 
ment on baseline hormone levels and response to the TRH test. The dos¬ 
age in CPZ equivalents was correlated with the other variables of inter¬ 
est by Pearson correlation coeffecients. Then the subjects were 
subdivided into two groups (high and low), based on the median value of 
CPZ equivalent dose. The means of these two groups on the variables of 
interest were compared by Student's t-test. The same analyses were done 
using the duration of antipsychotic treatment as the variable. 
The groups in the study were then subdivided by diagnosis into schiz¬ 
ophrenics and schizoaf fectives, and the means of the two groups on all 
variables of interest were compared for significant differences using 
Student's t-test. 
The chi-square statistic was used to compare blunted and non-blunted 
TSH responses to TRH in the study groups examined as well as to compare 
blunting status to diagnosis. Due to the small numbers of observations, 
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Yate's continuity correction for small numbers (Ferguson, 1979) was 
used. Fisher's exact test (two-tailed) was also calculated where appli¬ 
cable. 
All data analysis was done using the SAS (Statistical Analysis Sys¬ 
tem) package available at Yale Computing Center. 
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V. RESULTS 
A. Patient Population 
The TSH response to an infusion of TRH was studied in three distinct 
groups of subjects; schizophrenic and schizoaffective patients on no 
psychotropic medications, similar patients being treated with antipsy- 
chotics, and healthy controls on no psychotropic medications. The con¬ 
trol group (Study Group A) contained 14 healthy males from the commu¬ 
nity, aged 22-54 years. The group of patients on no psychotropic 
medications (Study Group B) included 8 male inpatients, aged 22-58. 
Five of these patients had been diagnosed as schizophrenic and three as 
schizoaffective. The third group (Study Group C) contained 11 inpa¬ 
tients on antipsychotic medications who ranged in age from 23 to 59. 
Six of these patients were schizophrenic and five were schizoaffective. 
The patients in Group C (on antipsychotics) received one of five dif¬ 
ferent drugs. Five were on perphenazine, three were on chlorpromazine, 
and one each was on haloperidol, trifluoperazine, and thiothixene. In 
addition to the antipsychotics, 7 of 11 patients in Group C were also 
taking anticholinergics to control antipsychotic side effects. One of 
these 7 patients was also receiving a benzodiazepine (Restoril brand 
temazepam) and an antihistamine (Benadryl brand diphenhydramine). Sev¬ 
eral subjects in Group A (controls) were taking other medications for 
physical conditions, none of which are thought to exert a major influ¬ 
ence on the TRH test. These included one patient taking a diuretic and 
analgesic, one on a diuretic and beta-blocker, and one each on an anti- 
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biotic, a mucolytic, an antihistamine, an analeptic, and nitroglycerin 
(see Appendix G for details). 
The three groups were compared with regard to demographic variables 
in order to assess their homogeneity and in light of the fact that at 
least one of these variables, specifically age, is known to be related 
to response to the TRH test. The subjects ages ranged from 22 to 59, 
and the mean age did not differ significantly among the groups by Stu¬ 
dent's t-test. The group means of height and weight were then compared 
and were also found to be not significantly different (see Table 1). 
B. Baseline Hormonal Levels 
The baseline levels of FT^, TT^, TSH, and PRL before the TRH stimulation 
test were compared among study groups and some differences were noted 
(see Table 1). The mean free T^ level of Group B (unmedicated) was 
1.32 yU/ml, which was significantly lower than the mean of 1.51 yU/ral 
found in the control group (p<.03). The mean FT^ of Group C (on antip- 
sychotics) was 1.40 yU/ral, which fell between the other two groups and 
did not differ significantly from either. 
The total T^ levels did not differ significantly among the groups, 
although the same relative order was observed as for FT^, with the 
unmedicated group having the lowest mean TT^ (7.34 ng/ml) followed by 
the patients on medications (7.62 ng/ml) and then the controls with the 
highest mean (8.05 ng/ml). 
Baseline TSH levels showed no significant difference among groups, 
although the relative rank order of the means was the same as the FT^ 
and TT. means. 
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The means of the the baseline PRL levels were compared across groups, 
and as expected, the mean of Group C (on antipsychotics) was 12.36 
ng/ml, which was higher than the mean of 6.56 ng/ml found in Group B (no 
medications), at a significance level p<.02. The mean PRL level of 
Group C (on medications) was also higher than controls, and the differ- 
ance was close to being significant (p<.0549). Controls did not differ 
significantly from the unmedicated group. A significant negative corre¬ 
lation between baseline PRL and age was noted in Groups A and B. In 
Group C this correlation was in the same direction but did not reach 
significance (p<.06). As mentioned in the methods section, baseline 
prolactin levels were not determined for all subjects, but were measured 
for 10 of 14 controls, all 8 subjects on no medications, and 10 of 11 
patients on medications. All analyses involving PRL or APRL were 
r y ° max 
based on these numbers. 
C. Results of the TRH Test 
1) Patients on antipsychotics compared those on no medications 
The effect of antipsychotics on the TSH response to TRH was analyzed by 
comparing the mean ATSH of the three study groups. The mean ATSH 
max max 
of Group C (on antipsychotics) was 8.31 yU/ml, which did not differ sig¬ 
nificantly from the Group B (no medications) mean of 8.35 yU/ml. Also, 
the mean ATSH of Group A (controls) was 9.92 yU/ml which did not dif- 
fer significantly from either patient group. These data are presented 
in Table 2, and the mean ATSH values for the three groups is shown 
graphically in Figure 1. 
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The other dependent variable of TSH response, area under the curve, 
was compared among study groups, and no significant differences were 
found. The mean area under the curve was 266 for controls, 274 for 
unmedicated patients, and 255 for patients on antipsychotics. The 
ATSH and Area Under Curve values were found to be highly correlated 
max 
in each of the three study groups (p<.0001 in each case), indicating 
that both these dependent variables (which were intended to measure TSH 
response to TRH) were likely measuring the same thing. 
The group means of the APRL^ response to TRH were also examined. 
Five patients did not have values, as discussed above, and were not 
included in this analysis. The group APRL means were not signifi- 
max 
cantly different, although the mean of the medicated group (38.0 ng/ml) 
was slightly higher than the unmedicated group (27.2 ng/ml), and the 
mean of the controls was intermediate (34.6 ng/ml) 
After comparing the group means for the two main dependent variables, 
ATSH and Area Under Curve, the groups were subdivided with respect to 
max c r 
their ATSH response. Using the criterion of a ATSH of <6 yU/ml as 
m 3.x m 3x 
defining a blunted response, blunting was found in 2 of 12 controls, 3 
of 8 unmedicated patients, and 3 of 11 patients on antipsychotics. 
The blunted subjects in all three study groups were then pooled and 
compared to non-blunted subjects with regard to the means of the demo¬ 
graphic variables and baseline hormone levels using Student’s t-test. 
The blunted subjects were found to be significantly older than non- 
blunted subjects with a mean age of 44.5 years as compared to 34.7 years 
for the non-blunters (p<.03). The baseline TSH levels of the blunted 
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subjects was 2.69 yU/ml, compared to 3.45 yU/ml in the non-blunted sub¬ 
jects, but this difference did not reach significance (p<.06). Blunters 
also tended to have a lower baseline prolactin level (6.58 ng/ml in 
blunters compared to 10.20 ng/ml in non-blunters), but again this dif¬ 
ference did not reach significance (p<.08). It must be kept in mind 
that these differences were found when pooling blunters and non-blunters 
of all study groups. When the blunters in the two patient groups 
(Groups B and C) were compared to the non-blunted controls, no signifi¬ 
cant differences in demographic variables or mean baseline levels of 
FT^, TT^, TSH, or PRL were found. When looking at the blunters in 
Groups B and C separately, compared to non-blunted controls, the numbers 
became very small, which increased the likelihood of type II error. The 
three blunted subjects in Group B (no medications) did not differ from 
non-blunted controls on any variables. However, the mean baseline TSH 
level of the three blunted subjects in Group C (on antipsychotics) was 
2.10 yU/ml, which was significantly less than the baseline TSH of the 12 
non-blunted controls (3.41 yU/ml), at a significance level of p<.02. 
The numbers of blunted and non-blunted subjects in each of the three 
study groups were compared to the number in the other study groups, in 
pairs (i.e. A vs B, A vs C, and B vs C). This generated three 2X2 
tables which are presented in combined form in Table 3. The 2X2 
tables were analyzed for independence between blunting status and study 
group using Fisher's exact test and the chi-square statistic employing 
Yate’s continuity correction for small numbers (as discussed in the 
methods section). None of the comparisons was significant, indicating 
the null hypothesis of independence between blunting status of ATSH 
response and study group could not be rejected. 
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2) Effect of antipsychotic dosage 
The patients receiving antipsychotics were not all on the same dosage. 
The daily CPZ equivalents ranged from 240 to 1650. The mean dose was 
571 CPZ equivalents, and the median was 500. In order to look for dif¬ 
ferences in the TRH stimulation test related to antipsychotic dosage, 
Pearson correlation coefficients were calculated between CPZ equivalent 
dosages and all variables of interest including demographic variables, 
baseline hormone levels, ATSH , and Area Under Curve. None of these 
max 
correlations was significant. 
The patients on antipsychotics were then subdivided into two dosage 
groups (low and high), based on the median dose of 500. Three patients 
were receiving 500 CPZ equivalents and were included in the high group. 
Therefore, there were five patients in the low group and six in the high 
group. Means of all variables of interest were calculated for each 
group and compared (see Table 4). No significant differences were noted 
on any variable. The actual medication, dosage, CPZ equivalent dosage, 
and response to the TRH test of each subject is given in Table 5. 
3) Effect of duration of antipsychotic intake 
If antipsychotics taken for long periods have a different effect than 
those taken for relatively short periods, the response to the TRH test 
observed may have been affected by this factor. The duration of treat¬ 
ment of the subjects in this study ranged from 1 week to 13 years. An 
examination of the duration of treatment of all patients showed that 
there was a bimodal distribution, with patients clearly falling into one 
of two groups. The groups of patients with relatively short lengths of 
62 
c 
treatment contained 5 patients on antipsychotics from 1 to 7 weeks, with 
a mean length of treatment of 3 weeks. The other group contained 5 
patients who had been continuously on antipsychotics for 28 to 676 
weeks. The mean length of treatment was 308 weeks. One patient was not 
included in the analysis because the exact length of treatment was not 
determined. 
The mean values of all variables of interest were determined for 
these two groups and compared. No significant differences were seen. 
The long-term treatment group tended to be on a slightly higher dose of 
antipsychotic, but the difference was not significant (see Table 6). 
The duration of treatment of all patients on antipsychotics was also 
correlated to all variables of interest. The only significant correla¬ 
tion found was a negative one between duration of treatment and height 
(p<.03) . 
D. Diagnostic Groups 
As mentioned in the methods section, the study groups were composed of 
patients with RDC diagnoses of schizophrenia and schizoaffective disor¬ 
der. The unmedicated group of 8 contained 3 schizoaffective and 5 
schizophrenic patients, while the group of 11 patients on medications 
consisted of 5 schizoaffective and 6 schizophrenic patients. The data 
was examined separately by diagnosis in order to find any characteristic 
differences in TRH test results between schizophrenics and schizoaffec- 
tives. 
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There were no significant differences in the means of age, height, or 
weight between the two diagnostic groups when analyzed without regard to 
medication status (Groups B and C combined), nor were there any signifi¬ 
cant differences between them in either study group alone (see Table 7). 
The mean ATSH^^ values of the patients with each diagnosis are pre¬ 
sented in Figure 2. There was also no significant differences in base¬ 
line TT^, FT^, or TSH. The schizoaffectives were found to have a sig¬ 
nificantly higher PRL than the schizophrenics. However, it must be 
noted that a higher percentage of schizoaffeetives (63%) were on antip- 
sychotics than schizophrenics (55%). Antipsychotics are known to raise 
PRL levels, as discussed in the introduction. The numbers were so small 
as to make comparisons of the means of schizoaffectives and schizophren¬ 
ics within each group (Group B--on medications, and Group C--no medica¬ 
tions) not very meaningful, but prolactin was not significantly differ¬ 
ent between the diagnostic groups when examined in Group B and Group C 
separately. 
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VI. DISCUSSION 
A. The TRH Test in Patients on No Medications 
This study found no evidence of significant differences in the TSH 
response to TRH of schizophrenics and schizoaffectives on no medications 
as compared to healthy controls. This is in line with most other stud¬ 
ies in the literature, which have found normal TRH test results in 
schizophrenics and schizoaffectives (Loosen et al., 1977; Prange et al., 
1979; Extein et al., 1980; Loosen and Prange, 1979; Gold et al., 1981; 
Targum, 1983). These studies were discussed in greater detail in the 
introduction. Only one study was found which reported a significantly 
diminished TSH response to TRH in patients on no medications (Langer et 
al., 1983). The subjects in this study were 21 "paranoid-hallucinatory" 
females, a category which included patients diagnosed as manic, schi¬ 
zoaffective and schizophrenic by RDC. The authors report that 4 out of 
the 11 patients (36%) who were diagnosed as schizophrenic showed a 
blunted TSH response. The mean TSH response for the whole group was 
reported to be significantly less than normal controls, but results were 
not broken down by diagnostic category. Therefore, the reported result 
may have been influenced by a high proportion of blunting in the manic 
patients, making the findings of this study difficult to interpret. So 
on the whole, the literature is in agreement that unmedicated schizo¬ 
phrenics have normal responses to the TRH test. 
B. Effects of Antipsychotic Presence or Absence 
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The literature is less clear with respect to the effect of chronic 
antipsychotic treatment on the TRH test, since few studies on this ques¬ 
tion have been done and they have found conflicting results. The pres¬ 
ent study found no significant differences in TRH test responses between 
patients on antipsychotic medications and normal controls. This is in 
agreement with the findings of Naber et al. (1980a, 1980b, 1980c) and 
Braddock and Blake (1981) but differs from the findings of some other 
studies (Lamberg et al., 1973; Extein et al., 1982; Langer et al., 
1983). 
The study by Naber et al., reported in three papers (1980a, 1980b, 
1980c), looked at the TRH test responses of 22 chronic schizophrenics. 
The mean response found in the patients was compared to normal values 
reported in the literature by other workers. Since the exact procedure 
used in the TRH test varies, leading to different observations, the 
findings would have been more convincing if this study had included con¬ 
trols. This is especially true since submaximal doses of TRH were used 
(200 ug), and it is known that the response to a submaximal dose of TRH 
can be affected by body weight. Therefore, more variable responses are 
seen, as well as a smaller overall mean ATSH . Also, the TRH was co¬ 
max 
administered with LHRH in this study, which is a confounding variable, 
even though it is not said to affect the TSH response to TRH. 
The study by Braddock and Blake (1981) reports the TSH response to 
the TRH test in schizophrenics to be normal, but does not give any num¬ 
bers . 
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Two studies have found the mean TSH response to TRH to be signifi¬ 
cantly decreased in patients on antipsychotics (Lamberg et al., 1973; 
Extein et al., 1982). The Lamberg study compared results of chronic 
schizophrenic patients to a group of controls consisting of patients 
hospitalized with a variety of physical disorders. This study only 
measured TSH levels of 2 serum samples taken 20 and 60 minutes after TRH 
infusion. Since most researchers have found the peak response occurs at 
about 30 minutes, the samples tested by these researchers may have 
missed the peak ATSH values. Submaximal doses of TRH were also used in 
this study. The Lamberg group also gave a TRH test to a group of unmed¬ 
icated schizophrenics, then treated them with CPZ for 8 days and 
retested them. They found a decrease in mean ATSH which was not sig- 
nificant. The second test may have been influenced by the short period 
of time between tests, which would tend to cause decreased responses 
(Winokur et al., 1984). 
The study by Extein et al. did use supramaximal doses of TRH and com¬ 
pared the results of the schizophrenics to healthy controls. The schiz¬ 
ophrenics, the majority of whom were on antipsychotics, were reported to 
have a significantly lower mean of the Log of ATSH^^. This is the only 
study in the literature which used Log of ATSH as a dependent vari¬ 
able, which was done because the ATSH values were not normally dis- 
tributed, according to the authors. 
One other study apparently found an increase in the TSH response to 
TRH while schizophrenic patients were on antipsychotics (Langer et al., 
1983). This study did not report the mean TSH responses, but the number 
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of blunted responses to TRH were noted to decrease after treatment with 
antipsychotics, although the exact numbers are not given since the study 
did not differentiate between schizophrenics, schizoaffectives, and man- 
ics . 
So, in summary, two studies have reported no difference in TRH test 
results between schizophrenics on antipsychotics and controls, two stud¬ 
ies have reported decreased TSH response, and one study reported an 
increase. 
Although the studies on long-term treatment with antipsychotics are 
not in agreement, studies on the acute effects of antipsychotics and 
other DA-antagonists have generally found them to cause increased TSH 
response to TRH, as discussed in the introduction. This is thought to 
be a direct result of the DA-blocker activity of these drugs, since DA 
is a tonic inhibitor of TSH release. The drugs which have been found to 
cause an increased TSH response to TRH after acute administration in 
humans include metoclopramide (Scanlon et al., 1979; Rojdmark, 1983), 
domperidone (Wentzel and Doring, 1982), chlorproraazine (Kirkegaard et 
al, 1977), and haloperidol (Kirkegaard et al., 1978). However, animal 
studies have found that the antipsychotic trifluoperazine inhibits TSH 
response to TRH by a mechanism distinct from its DA-receptor blocking 
activity. This drug binds to calmodulin and blocks its action. Calmo¬ 
dulin is involved in mediating the cellular response to TRH in thyro- 
tropes (Fleckraan et al., 1981; Thaw et al., 1982; Powell et al., 1983; 
Sand et al., 1983). Thus the net effect of these drugs may depend on 
their relative activity as DA receptor blockers and calmodulin blockers. 
68 

I 
as well as the dynamic state of the thyrotrope with regard to the rela¬ 
tive influence of DA inhibition and TRH stimulation. So although there 
are theoretical reasons to expect either an increased or decreased TSH 
response to TRH after administration of DA-antagonists, based on their 
known pharmacological actions, studies in humans have generally found 
acute administration to result in an increased TSH response. 
C. Effects of Antipsychotic Dosage 
The present study found no correlation between antipsychotic dosage and 
response to the TRH test, in agreement with the findings of Naber et al. 
(1980c). That was the only other study found in the literature which 
converted antipsychotic dosage to CPZ equivalents and examined dosage as 
a continuous variable. The medication dosage of all the patients in the 
present study was in the generally accepted theraputic range, so the 
effects of very small doses as well as extremely large doses was not 
examined. However it would be most useful clinically to know whether 
antipsychotics affect the TRH test in the range of dosages seen in prac¬ 
tice. This study, as well as the one by Naber's group, seems to indi¬ 
cate that dosages within the usual theraputic range do not affect the 
results observed. 
D. Effects of Duration of Antipsychotic Treatment 
This study did not find a relationship between the duration of treatment 
with antipsychotics and response to the TRH test, which is in agreement 
with Naber et al. (1980c). A wide range of treatment durations were 
seen in the patients in the present study, and because they fell natu¬ 
rally into two groups ranging from one to seven weeks and eight or more 
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weeks of treatment, the results were analyzed by comparing these two 
groups as well as by using treatment duration as a continuous variable. 
Because of the similarity of the two groups on demographic variables and 
baseline hormones, the likelihood of other confounding variables affee¬ 
ing the findings is reduced. 
E. Effects of Diagnosis 
Many of the studies in the literature have grouped schizophrenics and 
schizoaffectives together in studies on the TRH test, but not all have 
analyzed the findings separately to look for differences between these 
two groups of patients. This study did not find any differences in TRH 
test results between schizoaffectives and schizophrenics, either on or 
off medications. Although the sample size of each diagnostic category 
is small, these findings agree with those of Gold et al. (1981). There 
were also no differences found in demographic variables or baseline hor¬ 
mone levels between the diagnostic groups with the exception of baseline 
PRL levels, which were higher in schizoaffectives. This could be 
explained by the fact that 63% of the schizoaf fectives were on medica¬ 
tions while only 55% of the schizophrenics were on medications. When 
diagnostic groups were compared separately in the groups on or off 
antipsychotics, the difference was not seen. 
The finding of no difference between diagnostic groups may be impor¬ 
tant clinically, since distinguishing schizoaffectives from the affec¬ 
tive disorders by the TRH test would be as important as distinguishing 
schizophrenics, and if schizoaffectives are shown to behave like schizo¬ 
phrenics on the TRH test, this diagnostic differentiation would be pos¬ 
sible. 
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F. Other Factors 
Although age was not correlated to ATSH values, it was found that 
the mean age of blunters, determined by combining the subjects with 
blunted responses from all groups, was higher than the mean age of non- 
blunters. So apparently age did have some mild influence on the 
results, even though the study had been limited to subjects under age 60 
to minimize this effect. This finding is consistent with other studies 
in the literature (Snyder and Utiger, 1972; Loosen et al., 1977). Per¬ 
haps as the TRH test becomes more widely used, a correction factor for 
age could be developed to minimize its effect on results, thereby making 
the test more powerful. 
This study also found a lower mean FT^ in patients on no medications 
compared to controls, as well as a lower mean FT^ in patients on antip- 
sychotics, although the difference was significant only in the group of 
patients on no medications compared to controls. These variations in 
baseline thyroid hormones found between patients and controls is another 
confounding variable to be kept in mind when interpreting the results. 
Other researchers have reported similar findings. The study of TRH 
testing in 30 schizophrenics by Extein et al. (1982) reported that the 
TT^ and FT^I of the patients was significantly lower than controls. If 
this was because the patients tended to be slightly hypothyroid, a 
greater than normal response to the TRH test would be predicted. How¬ 
ever the study found a significantly lower response. Unless some of 
these patients had secondary hypothyroidism, which is extremely rare, 
the findings are more consistent with the presence of some other form of 
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thyroid disturbance such as those discussed in the introduction. These 
disturbances have been described in ill patients with non-thyroidal dis¬ 
orders, and have been termed the euthyroid sick syndrome (ESS) by some. 
Another study (Prange et al., 1979) found low mean TT^ in schizo¬ 
phrenics as compared to controls. This is further support that some 
disturbances in thyroid function may be common in psychiatric patients. 
Prange's group also found a significantly higher FT^I in patients, but 
found that this was due to diminished T^ binding sites rather than 
increased TT.. 
4 
Since one of the primary disturbances found in patients with abnormal 
thyroid indices is decreased extrathyroidal conversion of T^ to T^, the 
most consistent abnormal laboratory findings are a low T^ and high rT^. 
Various measures and estimates of T^, including TT^, FT^, and especially 
FT^I, are sometimes misleading. The levels of TT^ may be high, low or 
normal as a result of secondary compensation, decreased metabolism, 
changes in the relative concentration of binding proteins, displacement 
from binding proteins by an unknown inhibitory factor, and other changes 
in thyroid physiology which are not well understood (Larsen 1984). The 
FT^I is an estimated value based on certain assumptions about relative 
proportions of binding proteins and their affinities which do not hold 
true in ESS. Thus, while the findings of abnormal T^ parameters in 
schizophrenics is interesting, the low T^ findings in Prange's study is 
even more suggestive of the thyroid abnormalities characteristic of 
those found in ill patients. 
G. Limitations of the Study 
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There are several factors in the design and methodology of the study 
which may limit the generalizability of its findings. Some of them have 
already been mentioned, but the following section reviews these and 
other points along with the steps taken to minimize their influence. 
1) Sample size 
It is always desirable in any study to have the largest sample possible 
in order to be more confident about the reliability of the findings. 
However, practical considerations limited the number of subjects in this 
study to 33. There were several reasons for this, including the diffi¬ 
culty of obtaining informed consent from severely disturbed individuals, 
the necessity of excluding those who had taken lithium or other drugs 
which may have influenced the result, and a limited amount of time and 
resources for conducting the study. In any case, the number of subjects 
in the present study compares favorably with many in the literature, and 
the cumulative findings of many such studies adds to the overall body of 
knowledge. 
2) Study design 
The study was not a true experiment, but was in fact a correlational 
design which compared an observed variable (response to TRH stimulation) 
in three naturally distinct groups. This type of design is termed a 
Static-Group Comparison by Campbell and Stanley (1963). Ideally, it 
would have been desirable to perform a true experiment by randomly 
assigning previously drug-free patients as well as controls to either a 
drug-free or antipsychotic treatment group for a specified length of 
time and then performing the TRH stimulation test. This would have min- 
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imized problems with confounding variables, and would have allowed 
statements of causality as well as statements of correlation. However, 
in doing studies with human subjects, experimental design must often be 
modified due to ethical considerations. Withholding antipsychotic medi¬ 
cations, which are of proven theraputic benefit, from psychotic patients 
for long periods of time would be unethical. In addition, giving antip- 
sychotics to normal controls for long periods of time would not be ethi¬ 
cally justified in light of the known side effects, including acute 
dystonic reactions, tardive dyskinesia, and anticholinergic side 
effects. 
Still, correlational studies can be valuable as long as the limita¬ 
tions are kept in mind when interpreting the results. In discussing the 
findings of this study, I attempted not to make statements which could 
not be justified given the design of the study. 
3) Appropriate controls 
In order to minimize differences between groups attributable to factors 
other than the ones of interest, it is desirable to use a control group 
as similar to the group(s) under study as possible. At times is is not 
clear what the most appropriate control group would be. In the present 
study, two groups of inpatients were compared to a control group of 
healthy outpatients. Hospitalization may have been a factor affecting 
the two inpatient groups differently from controls. It would have been 
desirable to use healthy hospitalized subjects as controls, but healthy 
people are not generally hospitalized, and hospitalizing controls spe¬ 
cifically for the purpose of this study was not feasible. Perhaps 
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patients hospitalized with physical disorders could have been used as 
controls as some other researchers have done (eg. Lamberg et al., 1977; 
Extein et al., 1982, 1983) but this introduces the illness of the con¬ 
trols as another souce of variability. 
In this study an attempt to minimize the effect of hospitalization 
was made by performing the TRH test as soon as possible after hospitali¬ 
zation, often within the first two or three days. The controls may also 
have differed in other respects from the subjects since the controls 
were mostly employees of the hospital, students, and researchers, who 
tended to be of higher social, economic, and educational standing than 
the subjects. However, the mentally ill are known to drift to a lower 
socioeconomic status, probably as a result of their illness, and so the 
differences seen may have been a reflection of the effect of illness on 
the subjects. 
The similarity between all groups with regard to age, height, weight, 
and baseline hormonal values gives some basis for the assertion that the 
comparability of the groups was good. 
4) Duration of antipsychotic treatment 
The length of treatment with antipsychotics varied widely in the study. 
If chronic antipsychotic treatment has a different effect than rela¬ 
tively short-term treatment, the group of patients on medications may 
not have been homogeneous. Although there is little research on the 
relationship between length of antipsychotic treatment and hypothalamic- 
pituitary-thyroid parameters, research on the relationship between 
length of treatment and prolactin discussed in the introduction shows 
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evidence that the effect of antipsychotics on prolactin reaches a pla¬ 
teau and then remains stable indefinitly. There is no reason to expect 
that the pituitary thyrotropes behave in a manner greatly different from 
lactotropes in response to long-term antipsychotic treatment. In any 
event, patients' responses to the TRH test were analyzed with respect to 
duration of treatment in order to detect any systematic differences. 
5) Choice of blunting criterion 
Researchers have used different levels of ATSH to define a blunted 
max 
response, generally ranging from <5 yll/ml to <7 yU/ml. At times, the 
level of C<C2 CmCU/ml has been used, generally when submaximal doses of 
TRH were given (eg. the studies by Naber et al.) since the ATSH J max 
response tends to be less in all patients. Of researchers using supra¬ 
maximal TRH doses, the blunting criteria is generally between <5 yU/ml, 
as in all the studies by Loosen and Prange's group, or <7 yU/ml as in 
the studies by Extein and Gold's group. Using the level of <6 yU/ml as 
the criteria in this study seemed to be a reasonable compromise. How¬ 
ever, the data analysis emphasized mean ATSH values, treating them as 
continuous variables, rather than dichotomizing the patients into 
blunted and non-blunted groups, although the numbers of patients showing 
blunted responses are reported. 
6) Diagnostic categories studied 
Both schizophrenics and schizoaffectives were studied and data were ana¬ 
lyzed separately and for both diagnostic groups combined. Although 
schizoaffectives clearly differ from schizophrenics, in many ways they 
are similar. As Meltzer (1984) indicates in his review of biological 
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studies of schizoaffective disorders, in some respects these patients 
appear more similar to those with affective disorders and in other 
respects they are more similar to schizophrenics. 
It seems valid to include schizoaffectives in the analysis, as this 
study and others have done, since the TRH test in clinical practice 
would likely be used to distinguish between manics and depressives on 
one hand, and schizophrenics and schizoaffectives on the other. How¬ 
ever, possible differences between the two diagnoses were kept in mind 
when the data were examined. 
7) Other factors 
As discussed in the introduction, there are many factors which are known 
to affect the TSH response to TRH. If the study groups differ with 
respect to any of these variables, they would become plausible alterna¬ 
tive hypotheses for the findings. Therefore, attempts were made to min¬ 
imize differences on any of these variables. The study was limited to 
males to minimize the effects of variation in estrogen and testosterone 
levels. An age range of 20-60 was established since it is known that 
elderly males have a decreased TSH response to TRH, and age was examined 
as a possible confounding variable. 
All tests were done at the same time of day to minimize effects due 
to circadian rhythms, although if individual patients had radically dif¬ 
ferent sleep/wake cycles, they may have been at different points in 
their particular circadian rhythm. However, this would affect the 
results only to the extent that there were systematic differences 
between groups, which we did not have reason to expect. 
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Variations in baseline thyroid hormone levels would have an influence 
on response to the TRH test. Since all subjects were clinically euthy¬ 
roid and anyone with clearly abnormal TFT's was excluded, an effect due 
to thyroid hormone levels was not expected. In fact there may have been 
some subtle differences in baseline thyroid parameters between groups, 
which is examined in the results and discussion sections. 
Another factor which can affect the test is stress. The psychiatric 
patients may have been under more stress than the controls due to their 
illness, which could have affected their results. However, this factor 
cannot easily be manipulated in psychiatric patients, and in order for 
the TRH test to be useful clinically, variations in stress level should 
not greatly affect its ability to provide useful information. Perhaps 
using the TRH test clinically in conjunction with the Dexamethasone Sup¬ 
pression Test or Corticotropin Releasing Factor Stimulation Test will 
provide complimentary information. The procedure was designed to mini¬ 
mize any extraneous stress by having the subjects lying down comfortably 
throughout the test procedure. 
No subject taking a medication known to have a major affect on TFT's 
was included. In addition, since the effects of lithium on thyroid 
function may last for a considerable period of time after discontinua¬ 
tion, no one who had received lithium in the four months prior to the 
TRH test was included. Seven of the 11 patients on antipsychotics were 
concurrently receiving anticholinergics, but these medications are not 
known to affect the hypothalamic-pituitary-thyroid axis. Subjects in 
the study were on a variety of non-psychotropic medications for medical 
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conditions, but only one or two were taking any particular class of 
medication (including two on antihistamines, two on diuretics, and one 
each on an antibiotic, beta-blocker, benzodiazepine, analgesic, analep¬ 
tic, mucolytic, and nitroglycerin). This was not expected to alter the 
results systematically, but at most may have increased the variability 
of the observed responses somewhat. 
H. Possibilities for Future Research 
The findings of the present study suggest several areas which may be 
interesting for future research. Also, since practical and time consid¬ 
erations imposed some limitations on this study, future research with an 
expanded focus could extend the scope of the findings. 
The research to date on the effect of antipsychotics on the TRH stim¬ 
ulation test in psychiatric patients has involved a fairly small total 
number of subjects. The 19 patients who made up the present study con¬ 
stituted one of the larger groups studied, but it would still be desira¬ 
ble to increase the total number of subjects in the literature in order 
to increase the confidence level of the findings. Also, as the sample 
size increases, it becomes possible for more subtle differences between 
groups to become detectable. 
The clinical usefulness of the TRH test depends on being able to 
apply it both to males and females. The present study included males 
only, in order to limit sex as a possible confounding variable. How¬ 
ever, this means that the external validity of the findings is also lim¬ 
ited to males. Future work on the effects of antipsychotics on the TRH 
test in females should be able to determine whether sex modifies the 
test results. 
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Similarly, clinicians would like to be able to use the TRH test on 
patients of all ages who are taking antipsychotics, not just those 
between 20 and 60 as were used in this study. Since the TSH response to 
TRH is known to be decreased in elderly males, future studies could 
quantify how antipsychotics affect the normal variation in TSH response 
due to age. Perhaps future research could adopt different criteria for 
an abnormal response in specific patient groups in order to take into 
account the normal variations in the TSH response to TRH due to age and 
sex. It should be mentioned however that in this study, even though a 
ATSH^^ of <6 yU/ml was considered a blunted response, the study was 
mainly concerned with the actual magnitude of TSH response. Thus both 
the parameters, the TSH response to TRH and the dose of antipsychotics 
were treated as continuous variables. Thus an arbitrary cutoff level of 
TSH response becomes less significant than the actual ATSH observed over 
time. 
Although TRH is known to affect anterior pituitary hormones other 
than TSH, the present study was limited to an examination of the TSH 
response. The prolactin response was also measured, but this was prima¬ 
rily to gauge antipsychotic compliance, since the increase in baseline 
prolactin levels due to antipsychotic intake is well known. Indeed the 
mean baseline values of serum PRL were higher in patients on antipsy¬ 
chotics compared to those on no medication. Future research could exam¬ 
ine the possible effects of antipsychotics on the response of other 
anterior pituitary hormones to TRH stimulation (eg. GH and ACTH). The 
effect of an infusion of TRH on and response in patients on antip¬ 
sychotics is another area which could be studied in the future. 
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I. Summary 
The TRH stimulation test is becoming increasingly important in psychia¬ 
try. The TSH response to TRH promises to be useful in the diagnosis of 
affective disorders, and possibly in the differentiation of mania from 
schizophrenia. Since many of the patients on whom clinicians would be 
likely to perform the TRH test may be on antipsychotics, it is important 
to know whether these drugs interfere with the test results. This 
information would be useful not only to psychiatrists but to other 
health professional (eg. endocrinologists) who may need to perform a TRH 
test on an individual concommitantly taking antipsychotics. Since dopa¬ 
mine is an important neurotransmitter with effects on TSH dynamics, and 
most antipsychotics are DA receptor blockers, there is a theoretical 
basis for predicting that antipsychotics may have an effect on the TRH 
stimulation test. The existing literature on the effect of antipsy¬ 
chotic treatment on the TRH stimulation test is not in agreement. The 
number of studies that have been done is quite small, and they have var¬ 
iously reported decreased, increased, or unchanged TSH response to TRH 
stimulation in patients on antipsychotics. 
Some of the discrepancies in the literature may be the result of 
design and methodological problems. These studies have been discussed 
more fully in the introduction, but some of the more important methodo¬ 
logical flaws are summarized here. Several studies used submaximal TRH 
doses, which would result in more variable responses. Dependent vari¬ 
ables used have varied, from the Log of ATSH , to ATSH values of two 
max 
samples taken at times which may have missed some peak responses. Oth¬ 
ers did not control for circadian variation by always testing at the 
81 

same time of day, or did not consider age differences between patients 
and controls, despite a we 11-documented age effect on the TSH response 
to TRH. 
Another factor that may have contributed to the diverse findings is 
the relatively small sample size used in many of the studies, as well as 
the inclusion of both male and female patients. Although the study most 
similar to the present one (Naber et al., 1980c) included 22 patients 
(but no controls), compared to the 19 patients and 14 healthy controls 
in the present study, the subjects in Naber's study consisted of both 
males and females. One study (Extein et al., 1982) reported TRH testing 
in 30 schizophrenics but this group was also composed of both sexes. 
Other studies have reported on as few as five subjects (Extein et al., 
1980; Kirkegaard et al., 1978). 
Many of the studies in the literature reviewed did not include con¬ 
trols, but compared the TSH responses to TRH of the patients to values 
reported in the literature by other authors, who may have used a differ¬ 
ent procedure. 
Those studies which did include controls may not have always used the 
most appropriate ones. One study compared TRH test results of patients 
to controls using a heterogeneous collection of hospitalized patients as 
the control group. These patients actually had a variety of diagnoses 
including general paralysis, tremors, parkinsonianisra and mental retar¬ 
dation. 
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Another issue concerning some of the reported studies is that the 
patient groups investigated were not homogeneous in all cases. For 
example, the data from patients with a variety of distinct RDC diagnoses 
were analyzed together as a group in some studies. Some studies 
included both schizophrenics and schizoaffectives but unlike the present 
study, did not consider diagnosis as a possible confounding variable in 
the analysis. One study performed both the TRH stimulation test and 
LHRH stimulation test at the same time by injecting both substances 
simultaneously. Even though this practice is not thought to invalidate 
the results of either test in unmedicated healthy subjects, it would 
have been desirable not to add the additional variable of another 
releasing hormone while testing the effects of antipsychotic medication 
on the TSH response to TRH. Other studies performed repeated TRH test¬ 
ing weekly, although it is known that TRH infusion may affect subsequent 
testing for periods of at least a week. 
The present study was an attempt to clarify some of the discrepancies 
in the literature. An effort was made to minimize the effects of some 
of the confounding variables which may have influenced the findings of 
previous studies, including age, sex, TRH dose, testing procedure used, 
circadian variation, and so on. 
Patients included in the study were diagnosed by RDC as either schiz¬ 
ophrenic or schizoaffective. The medication history of all subjects was 
known including dosage, as well as duration of treatment for the 
patients on antipsychotics. Patients who had taken lithium (known to 
affect thyroid parameters) within the previous four months were 
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excluded. The test results of the patients were compared to those of 
healthy controls who had been given the TRH test using the same proce¬ 
dure as the psychiatric patients. A standardized TRH procedure was 
employed in this study, using supramaximal doses of TRH to insure a max¬ 
imal TSH response and to minimize variation due to differences in height 
and weight, and body surface area. All tests were done at the same time 
of day to minimize the effects of circadian variation in TSH response. 
The TSH response was measured at a sufficient number of time intervals 
over a period of two hours to insure an accurate assessment of the true 
TSH response. Only males were used in this study in order to minimize 
differences due to sex. An age limit of 20-60 was set (since the TSH 
response to TRH is known to decline with age in males), and comparison 
groups were age matched. 
As previously mentioned, several studies combined schizophrenics and 
schizoaffective patients in their analyses. The present study looked 
first at the two diagnostic groups separately and found no differences 
in their response to TRH testing, whether on or off antipsychotics. 
Although the numbers were small, no differences were seen. Subsequent 
analyses included patients in both diagnostic categories. 
This study also looked at the affect of the dose of antipsychotics 
(converted to CPZ equivalents) on the TRH test. Only one other study 
had done this (Naber et al., 1980c). However, that particular study had 
a number of flaws, which included using a submaximal TRH dose, adminis¬ 
tering LKRH at the same time, and including both males and females. 
That study was also the only one found in the literature which examined 
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the duration of antipsychotic treatment as an independent variable. 
They found that duration of treatment did not appear to TSH influence 
the response. 
The present study found no difference in TSH response to TRH between 
those patients on antipsychotics and those on no medications. Neither 
group differed significantly from healthy controls. In addition, no 
dosage effect was found in the present study. Finally, the duration of 
antipsychotic treatment was examined, both as a continuous variable and 
by dividing patients into two groups based on treatment duration (short 
and long term relative duration) and found no significant differences in 
TSH response to TRH. 
In conclusion, it appears that treatment with antipsychotic medica¬ 
tions does not interfere with the results of the TRH test as far as TSH 
response is concerned, since patients on these medications did not dif¬ 
fer significantly from those off medications, nor from healthy controls. 
In addition, antipsychotic dosage as well as duration of treatment do 
not appear to affect the TSH response. Although these findings need to 
be verified in larger numbers of patients, it appears that the TSH 
response seen in TRH stimulation testing of patients on antipsychotic 
medications is not affected by the drugs, so the test is valid for these 
patients, as well as for other psychiatric patients on no medications. 
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VII. TABLES 
Table 1 
Mean values of demographic variables and baseline hormonal 
levels in the three study groups, with paired t-tests 
Study Group | t-tests of group 
mean (± S.D.) | means* * 
1 
5 A 
1 
1 
B 
1 
c 
1 
1 1 
| A vs B | 
1 1 
1 
A vs C | B vs C 
1 
Age (years) 36.4 
(11.7) 
37.4 
(13.4) 
37.8 
(10.4) 
n.s. n.s. n.s. 
Height (in) 70.5 
(2.7) 
70.9 
(2.9) 
70.3 
(2.8) 
n.s. n.s. n.s. 
Weight (lbs) 201 
(47.9) 
182 
(29.7) 
185 
(15.4) 
n.s. n.s. n.s. 
Total T4 baseline 
(ng/ml) 
8.1 
(1.5) 
7.3 
(1.2) 
7.6 
(1.5) 
n.s. n.s. n.s. 
Free T4 baseline 
(yu/ml) 
1.5 
(0.19) 
1.3 
(0.15) 
1.4 
(0.17) 
2.41 
p<. 03 
n.s. n.s. 
TSH baseline 
(yU/ml) 
3.36 
(1.07) 
3.11 
(1.05) 
3.26 
(1.02) 
n.s. n.s. n.s. 
Prolactin** 
baseline (ng/ml) 
8.0 
(4.1) 
6.6 
(4.0) 
12.4 
(5.2) 
n.s. -2.05 
p<.055 
-2.59 
p<. 02 
APRLmax (ng/ml)** 34.6 
(25.6) 
27.2 
(17.2) 
38.0 
(27.3) 
n.s. n.s. n.s. 
Study groups: A. Healthy controls (n=14) 
B. Patients on no medications (n=8) 
C. Patients on antipsychotic medications (n=ll) 
* For t-tests, t-value is given with its probability (p < x) if significant 
or close to significance; n.s. = not significant. 
** Prolactin and APRLmax means are based on 10 subjects 
in group A, 8 in B, and 10 in C. 
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Table 2 
Response to TRH infusion: 
Mean ATSH , Area Under Curve, and APRL 
max max 
in the three study groups, with paired t-tests 
Study Group 
mean (± S.D. ) 
1 t- 
1 
tests of group 
means* * 
A 
1 1 
B | 
1 1 
c 
1 
| A vs 
1 
1 
B | A vs 
1 
1 1 
C| B vs C| 
1 1 
ATSHmax (yU/ml) 9.9 
(4.3) 
8.4 
(5.8) 
8.3 
(3.5) 
n.s. n.s. n.s. 
Area under TSH 
response curve 
266 
(112) 
274 
(182) 
255 
(100) 
n.s. n.s. n.s. 
Antipsychotic dose 
(CPZ equiv.) 
0 0 578 
(394) 
@ @ @ 
Study groups: A. Healthy controls (n=14) 
B. Patients on no medications (n=8) 
C. Patients on antipsychotic medications (n=ll) 
* For t-tests, n.s. = not significant. 
@ The groups were defined by their medication status, therefore a t-test 
is not meaningful in this instance. 
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Table 3 
Comparison of blunted and non-blunted ATSH 
max 
values in the three study groups* 
1 Group A 1 Group B | Group C | totals 
1 
Blunted ATSHmax 2 
1 
1 3 
1 
1 3 
1 
1 8 
1 
Non-blunted ATSHmax 12 
1 
1 5 
1 
1 8 
1 
1 25 
1 
Totals | 14 
1 
1 8 
1 
1 11 
1 
| 33 
* Each group was compared 
comparisons) by Fisher's 
not significant. 
to the 
exact 
remaining two groups 
test and chi-square. 
(three paired 
The results were 
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Table 4 
The effect of low vs. high antipsychotic dose 
on baseline variables and TRH-stimulated hormone levels. 
Mean dose of antipsychotic, in CPZ equ ivalents* (± S.D.) 
1 Low 1 High | t-tests of group 
1 n=5 1 n=6 | means 
Dose of 380 730 @ 
antipsychotic (108) (453) 
(CPZ eqiv) 
Range of Dose 240-480 500-1650 
Age (years) 37.2 38.3 n. s . 
(9.9) (11.6) 
Height (in) 70.6 70.0 n. s. 
(3.6) (2.4) 
Weight (lbs) 185 186 n. s. 
(14.8) (17.3) 
Total T4 baseline 7.7 7.6 n. s. 
(ng/ml) (0.82) (2.0) 
Free T4 baseline 1.4 1.4 n. s. 
(yu/ml) (0.19) (0.16) 
TSH baseline 3.30 3.23 n. s . 
(vU/ml) (0.67) (1.29) 
Prolactin** 12.0 12.7 n. s. 
baseline (ng/ml) (2.7) (7.3) 
ATSHmax (yU/tnl) 7.6 8.9 n. s. 
(2.3) (4.4) 
Area under TSH 246 263 n. s . . 
response curve (50) (134) 
APRLmax (ng/ml)** 37.1 38.9 n. s. 
(23.6) (33.4) 
*Patients were divided into two groups based on their antipsychotic dosi 
in CPZ equivalents; the median was used to divide the patients into 
those receiving < 500 and those receiving 500 or more CPZ equivalents 
** Prolactin and APRLmax means are based on 10 subjects 
(5 in each group). 
@ The groups were defined by CPZ equivalent dose, therefore the t-test 
not meaningful for this variable. 
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Table 5 
Antipsychotic dose, ATSH , and Area Under Curve 
r 3 ’ max 
for the 11 patients on antipsychotics 
Patient Antipsychotic CPZ equiv- ATSHmax Area Under 
and dose alents Curve 
1 perphenazine, 48 mg 480 6.5 221 
2 trifluoperazine, 15 mg 300 5.9* 214 
3 chlorpromazine, 570 mg 570 7.9 284 
4 perphenazine, 40 mg 400 
o
 
oo
 308 
5 perphenazine, 48 mg 480 11.5 290 
6 perphenazine, 24 mg 240 6.3 196 
7 perphenazine, 56 mg 560 14.3 401 
8 chlorpromazine, 600 mg 600 7.9 288 
9 haloperidol, 10 mg 500 4.0* 115 
10 thiothixene, 50 mg 1650 5.1* 133 
11 chlorpromazine, 500 mg 500 14.0 428 
* Denotes a blunted ATSH response. 
max 
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Table 6 
The effect of the duration of antipsychotic treatment 
on baseline variables and TRH-stimulated hormone levels. 
Mean duration of treatment* (± S.D.) 
| Short-term| Long-term | t-tests of group 
n=5 | n=5 | means 
Duration of 3.0 308 @ 
treatment (wks) (2.45) (275) 
Range 1-7 28-676 
Age (years) 38.8 37.4 n. s 
(12.9) (9.9) 
Height (in) 71.2 69.2 n. s 
(3.0) (2.9) 
Weight (lbs) 183 194 n. s 
(12.7) (9.2) 
Total T4 baseline 7.3 7.9 n. s 
(ng/ml) (0.68) (2.2) 
Free T4 baseline 1.4 1.3 n. s 
(uU/ml) (0.18) (0.18) 
TSH baseline 3.14 3.18 n. s 
(yU/ml) (0.92) (1.19) 
Prolactin 11.0 13.7 n. s 
baseline (ng/ml) (3.6) (6.6) 
ATSHmax (yU/ml) 7.3 8.2 n. s 
(2.8) (3.6) 
Area under TSH 226 250 n. s 
response curve (78) (103) 
APRLmax (ng/ml) 25.0 51.1 n. s 
(20.0) (29.3) 
Dose of 420 736 n. s 
antipsychotic (108) (525) 
(in CPZ eqiv) 
* The median length of treatment of 17 weeks was used to divide the patients 
into the two groups, but they fell naturally into these groups as can be se 
by the large gap in the range separating the groups, from 7 to 28 weeks. 
The treatment duration of one patient was not known, so n=10. 
@ Not meaningful because the groups were defined by duration of treatment. 
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Table 7 
Comparison of Schizophrenics and Schizoaffectives 
on baseline variables and TRH-stimulated hormone levels. 
Group means (± S.D.) 
1 Schizo- | Schizo- t-tests of group 
1 phrenic | affective | means 
1 n=l 1 n=8 j 
Age (years) 38.1 37.0 n. s . 
(14.4) (5.9) 
Height (in) 69.9 71.4 n. s . 
(2.7) (2.8) 
Weight (lbs) 178 191 n. s. 
(20.3) (23.0) 
Total T4 baseline 7.5 7.5 n. s . 
(ng/ml) (1.1) (1.8) 
Free T4 baseline 1.4 1.3 n. s . 
(yU/ml) (0.19) (0.11) 
TSH baseline 2.81 3.74 n. s. 
(uU/ml) (1.04) (0.68) 
Prolactin* 8.69 11.15 t= -0.948 p<.05 @ 
baseline (ng/ml) (4.4) (6.6) 
ATSHmax (yU/ml) 7.7 9.2 n. s. 
(5.3) (3.1) 
Area under TSH 251 281 n. s . . 
response curve (170) (74) 
APRLmax (ng/ml)* 35.0 31.0 n. s. 
(28.8) (15.7) 
* Prolactin and APRLmax means are based on 8 subjects in group B, 
and 10 in group C. 
@ Prolactin levels are affected by antipsychotics. Six of the 11 
schizophrenics (55%) were on antipsychotics (mean dose=658 CPZ equiv.) 
and 5 of the 8 schizoaffectives (63%) were on antipsychotics (mean 
dose=498 CPZ equiv.). 
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VIII. FIGURES 
ATSH 
max 
Figure 1 
Mean ATSH compared by medication status, 
max 
9.9 ± 4.3 8.4 ± 5.8 8.3 ± 3.5 
Controls No medication On antipsychotics 
n=14 n=8 n=ll 
No significant differences were found among the groups. 
93 

Figure 2 
ATSH 
max 
Mean ATSH by diagnostic group, 
max ° 
n=14 n=ll n=8 
No significant differences were found among the groups. 
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IX. APPENDICES 
A. Thyroid Function Parameters 
1) Normal values 
Total triiodothyronine (TT3) 
Free triiodothyronine (FT3) 
Total thyroxine (TT4) 
Free thyroxine (FT4) 
Free thyroxine index (FT4I) 
Baseline thyroid-stimulating 
hormone (TSH) 
Thyroxine-binding globulin (TBG) 
TSH response to TRH (ATSHmax) 
(from Fishbach, 1984) 
1.10-2.30 ng/ml 
2.50-3.90 pg/ml 
5-12.5 ng/ml 
1-2.3 ng/dl 
5.8- 10.6 (arbitrary units) 
1.9- 5.4 ylU/ml 
12-28 yg/ml 
> 5.0-7.0 yU/ml over baseline. 
(Varies according to 
researchers; the level used 
work was > 6.0 yU/ml.) 
2) Coefficients of variation and sensitivities of assays used 
intra-assay 
inter-assay 
sensitivity 
4.1% 
3.6% 
15 ng/ml 
TT. 4 
2.73% 
3.65% 
0.47 yg/dl 
FT. 4 
4.1% 
4.6% 
0.05 ng/dl 
TSH 
4.04% 
4.23% 
0.6 ylU/ml 
different 
in this 
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B. Drugs Interfering With Thyroid Hormone Function 
Interfere with thyroid hormone synthesis 
sulfonylureas 
p-aminosalicylie acid 
6-mercaptopurine 
nitroprusside 
sulfonamides 
phenlybutazone 
aminoglutethamide 
iodide 
Decrease TBG levels: 
glucocorticoids 
L-asparaginase 
androgens 
Increase TBG levels: 
estrogens 
heroin 
clofibrate 
methadone 
perphenazine 
Inhibit binding of T3 and T4 to TBG: 
salicylates phenylbutazone 
fenclofenac 
halofenate 
5-FU 
phenytoin 
mitotane 
Alter T3 and T4 uptake or metabolism 
phenytoin heparin 
PTU 
propanolol 
amiodarone 
glucocorticoids 
iopanoic acid, ipodate 
Interfere with GI absorption 
replacement: 
cholestyramine 
soybean flour 
of thyroid hormones in patients on thyroid 
cholestipol 
(From Kaplan, 1981) 
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C. Reasearch Diagnostic Criteria (RDC) 
These are the criteria formulated by Spitzer and Endicott (1977) and used in 
making diagnoses in this work. 
1. Schizophrenia 
A through C are required for the period of illness being considered. 
A. During an active phase of the illness (may or may not now be present) at 
least two of the following are required for definite and one for probable: 
(1) Thought broadcasting, insertion, or withdrawal (as defined in this man¬ 
ual) . 
(2) Delusions of being controlled (or influenced), other bizarre delusions, 
or multiple delusions (as defined in this manual). 
(3) Somatic, grandiose, religious, nihilistic, or other delusions without 
persecutory or jealous content lasting at least one week. 
(4) Delusions of any type if accompanied by hallucinations of any type for 
at least one week. 
(5) Auditory hallucinations in which either a voice keeps up a running com¬ 
mentary on the subject's behaviors or thoughts as they occur, or two or 
more voices converse with each other. 
(6) Non-affective verbal hallucinations (as defined in this manual) spoken 
to the subject. 
(7) Hallucinations of any type throughout the day for several days or inter¬ 
mittently for at least one month. 
(8) Definite instances of marked formal thought disorder (as defined in this 
manual) accompanied by either blunted or inappropriate affect, delusions 
or hallucinations of any type, or grossly disorganized behavior. 
B. Signs of the illness have lasted at least two weeks from the onset of a 
noticeable change in the subject's usual condition (current signs of the ill¬ 
ness may not now meet criterion A and may be residual symptoms only, such as 
extreme social withdrawal, blunted or inappropriate affect, mild formal thought 
disorder, or unusual thoughts or perceptual experiences). 
C. At no time during the active period (delusions, hallucinations, marked for¬ 
mal thought disorder, bizarre behavior, etc.) of illness being considered did 
the subject meet the full criteria for either probable or definite manic or 
depressive syndrome (criteria A and B under Major Depressive or Manic Disor¬ 
ders) to such a degree that it was a prominent part of the illness. (See cri¬ 
teria for Depressive Syndrome Superimposed on Residual Schizophrenia.) 
Subtypes of Present Period of Schizophrenia 
This section is for studies in which there is interest in subtypes of Schi¬ 
zophrenia for the present period of illness. 
la. Subtypes based on the course of the present period of Schizophrenia. The 
following four mutually exclusive categories should be considered for each sub¬ 
ject who currently meets the criteria for Probable or Definite Schizophrenia. 
Note: Some subjects diagnosed initially as Acute may later show a Subacute, 
Subchronic, or even Chronic course. 
(1) Acute Schizophrenia: A through C are required. 
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A. Sudden onset--less than three months from first signs of increasing 
psychopathology to any of the core symptoms (criterion A). 
B. Short course--continuously ill with significant signs of Schizophrenia 
for less than three months. 
C. Full recovery from any previous episode. 
(2) Subacute Schizophrenia: 
Course is closer to that of Acute Schizophrenia than that of Chronic Schi¬ 
zophrenia . 
Example: First episode with fairly rapid onset and duration of five 
months. 
Example: Second episode with onset for this episode over a period of six 
months and full recovery from first episode. 
(3) Subchronic Schizophrenia: 
Course is closer to that of Chronic Schizophrenia than that of Acute Schi¬ 
zophrenia . 
Example: Significant signs of Schizophrenia more or less continuously 
present for at least the past year. 
Example: Second period following a previous period from which he did not 
fully recover. 
(4) Chronic Schizophrenia: 
Significant signs of Schizophrenia more or less continuously present for at 
least the last two years. 
lb. Subtypes based on the phenomenology of the present period of schizophrenic 
illness. The following mutually exclusive subtypes should be considered for 
each subject who currently meets the criteria for Probable or Definite Schizph- 
renia, to describe the phenomenology of the present condition of the subject. 
The order here is hierarchical among the first four subtypes. 
(1) Paranoid 
Throughout the active period of the episode of illness the clinical picture 
is dominated by the relative persistence of or preoccupation with one or 
more of the following: 
1. Persecutory delusions. 
2. Grandiose delusions. 
3. Delusions of jealousy. 
4. Hallucinations with a persecutory or grandiose content. 
(2) Disorganized (Hebephrenic) 
A through C are required. 
A. Marked formal thought disorder (as defined in this manual). 
B. Either 1 or 2: 
1. Affect which is shallow, incongruous, or silly. 
2. Fragmentary delusions or hallucinations with content not organized 
into a coherent theme. 
C. Not associated with marked emotional turmoil except during exacerba¬ 
tion. 
(3) Catatonic 
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Throughout the active period of the episode of illness the clinical picture 
is dominated by any of the following catatonic symptoms: 
1. Catatonic stupor (marked decrease in reactivity to environment and reduc¬ 
tion of spontaneous movements and activity). 
2. Catatonic rigidity (maintains a rigid posture against efforts to move 
him) . 
3. Waxy flexibility (maintains postures into which he is placed for at least 
15 seconds). 
4. Catatonic excitement (apparently purposeless and stereotyped excited 
motor activity not influenced by external stimuli). 
5. Catatonic posturing (voluntary assumption of inappropriate or bizarre 
posture). 
(4) Undifferentiated (or Mixed) 
Period of illness meets the criteria for more than one of the previous sub- 
types or for none of them. 
(5) Residual 
This category should be used when an individual has had a period of illness 
in the past that met the criteria A for Schizophrenia but his clinical pic¬ 
ture now does not contain any prominent psychotic symptoms, yet residual 
signs of the illness persist, such as emotional blunting, extreme social 
withdrawal, eccentric behavior, or mild formal thought disorder. Delusions 
or hallucinations may be present, but are not prominent. 
If a subject who meets the criteria for Schizophrenia develops a full 
depressive syndrome, without an exacerbation of his schizophrenic symptoms, 
he should receive the additional diagnosis of Depressive Syndrome Superim¬ 
posed on Residual Schizophrenia. If there is a flareup of the psychotic 
symptoms, he should receive the diagnosis of Schizo-affeetive Disorder, 
Depressed Type, and the subtyping on the chronicity axis should reflect the 
duration of the schizophrenic-like symptoms. 
A through C are required for the period of illness being considered. 
A. Once had an active period of illness which met the criteria for Schi¬ 
zophrenia. 
B. The current clinical picture does not contain any prominent psychotic 
symptoms, although the subject may have some delusions or hallucina¬ 
tions . 
C. Signs of the illness have persisted (e.g., blunted or inappropriate 
affect, social withdrawal, eccentric behavior, strange or unusual per¬ 
ceptual experiences, mild formal thought disorder since the time of 
the active period. 
2. Schizo-affective Disorder, Manic Type 
This category is for subjects who have had an episode of illness that fulfills 
the criteria for manic syndrome (A and B) but who also had at least one of the 
symptoms suggesting Schizophrenia (listed here in C) concurrent with the manic 
syndrome. It includes chronic forms even though the term is sometimes limited 
to acute or episodic psychoses. It also includes forms in which the schizo¬ 
phrenic symptoms are of brief duration compared to the affective symptoms or 
the converse. The term Schizo-affeetive Disorder, rather than Schizophrenia, 
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is used to reflect the current uncertainty as to whether this condition is a 
subgroup of Schizophrenia or more closely related to affective illness. If the 
symptoms in C occur only during periods of alcohol or drug use or withdrawal 
from them, the diagnosis should be Other Psychiatric Disorder. To a great 
extent Schizo-affeetive Disorder, Manic Type is a category which helps "purify" 
the samples of schizophrenics and those of affective disorder. 
A through E are required for the episode of illness being considered. 
A. One or more distinct periods with a predominantly elevated, expansive or 
irritable mood. The elevated, expansive, or irritable mood must be relatively 
persistent and prominent during some part of the illness or occur frequently. 
It may alternate with depressive mood. If the disturbance in mood occurs only 
during periods of alcohol or drug intake or withdrawal from them, it should not 
be considered here. 
B. If mood is elevated or expansive, at least three of the following symptoms 
must be definitely present to a significant degree, four if mood is only irri¬ 
table. (For past episodes, because of memory difficulty, one less symptom is 
required.) 
(1) More active than usual--either socially, at work, at home, sexually, or 
physically restless. 
(2) More talkative than usual or felt a pressure to keep on talking. 
(3) Flight of ideas (as defined in this manual) or subjective experience 
that thoughts are racing. 
(4) Inflated self-esteem (grandiosity, which may be delusional). 
(5) Decreased need for sleep. 
(6) Distractibility, i.e., attention is too easily drawn to unimportant or 
irrelevant external stimuli. 
(7) Excessive involvement in activities without recognizing the high poten¬ 
tial for painful consequences, e.g., buying sprees, sexual indiscretions, 
foolish business investments, reckless driving. 
C. At least one of the following symptoms suggestive of Schizophrenia is pres¬ 
ent during the active phase of the illness: 
(1) Delusions of being controlled (or influenced) or of thought broadcast¬ 
ing, insertion or withdrawal (as defined in this manual). 
(2) Non-affective hallucinations of any type (as defined in this manual) 
throughout the day for several days or intermittently throughout a one 
week period. 
(3) Auditory hallucinations in which either a voice keeps up a running com¬ 
mentary on the subject's behaviors or thoughts as they occur, or two or 
more voices converse with each other. 
(4) At some time during the period of illness had more than one week when he 
exhibited no prominent depressive or manic symptoms but had delusions or 
hallucinations. 
(5) At some time during the period of illness had more than one week when he 
exhibited no prominent manic symptoms but had several instances of marked 
formal thought disorder (as defined in this manual), accompanied by 
either blunted or inappropriate affect, delusions, or hallucinations of 
any type, or grossly disorganized behavior. 
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D. Signs of the illness have lasted at least one week from the onset of a 
noticeable change in the patient's usual condition (current signs of the ill¬ 
ness may not now meet Criteria A, B, or C and may be residual affective or res¬ 
idual schizophrenic symptoms only, such as mood disturbance, blunted or inap¬ 
propriate affect, extreme social withdrawal, mild formal thought disorder, or 
unusual thoughts or perceptual experiences). 
E. Affective symptoms overlap temporally to some degree with an active period 
of schizophrenic-1ike symptoms (delusions, hallucinations, marked formal 
thought disorder, bizarre behavior, etc.). 
The following qualifying categories should be considered for each subject who 
currently meets the criteria for Probable or Definite Schizo-affective Disor¬ 
der, Manic Type. 
2a. Subtypes based on the course of the present period of Schizo-affective 
Disorder. The following four mutually exclusive subtypes should be considered 
for each subject who currently meets the criteria for Probable or Definite 
Schizo-affective Disorder. Note: Some subjects diagnosed initially as Acute 
may later show a Subacute, Subchronic, or even Chronic course. 
(1) Acute Schizo-affective Disorder: A through C are required. 
A. Sudden onset--less than three months from first signs of increasing psy¬ 
chopathology to any of the core schizophrenic symptoms (criterion C). 
B. Short course--continuously ill with significant signs of Schizophrenia 
for less than three months. 
C. Full recovery from any previous episode. 
(2) Subacute Schizo-affective Disorder: 
Course is closer to that of Acute than that of Chronic Schizo-affective Dis¬ 
order. 
Example: First episode with fairly rapid onset and duration of five 
months. 
Example: Second episode with onset over a period of six months for this 
episode and full recovery from first episode. 
(3) Subchronic Schizo-affective Disorder: 
Course is closer to that of Chronic than that of Acute Schizo-affeetive Dis¬ 
order . 
Example: Significant signs of Schizophrenia more or less continuously 
present for at least the past year. 
Example: Second period following a previous period from which he did not 
fully recover. 
(4) Chronic Schizo-affective Disorder: 
Significant signs of Schizophrenia more or less continuoulsy present for at 
least the last two years. 
2b. Temporal relationship of affective and schizophrenic-like features for 
current episode. 
(1) Mainly schizophrenic: Either A or B. 
A. Core schizophrenic symptoms listed under C in the Schizo-affective cri¬ 
teria were present for at least one week in the absence of manic or 
depressive features. 
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B. Prior to the onset of the affective features, subject exhibited the 
following features which are often associated with Schizophrenia: social 
withdrawal, impairment in occupational functioning, eccentric behavior, 
emotional blunting, or unusual thoughts or perceptual experiences. 
(2) Mainly affective: A and B are required. 
A. Schizophrenic-1ike symptoms listed under C in the Schizo-affective cri¬ 
teria developed simultaneously with or followed manic or depressive symp¬ 
toms and never were present for a period of at least one week in the 
absence of the manic or depressive symptoms. 
B. Good premorbid social and occupational adjustment 
(3) Other: Does not clearly fit either (1) or (2). 
2c. Length of time from first signs of increasing psychopathology to any of 
the core schizophrenic symptoms noted in C. (If more than one episode, most 
recent.) 
1. Less than 2 days 
2. Less than 1 week 
3. Less than 1 month 
4. Less than 2 months 
5. More than 2 months 
3. Schizo-affective Disorder, Depressed Type 
This category is for subjects with an episode of illness that fulfills the cri¬ 
teria for a full depressive syndrome (A and B) but who also have at least one 
of the symptoms suggesting Schizophrenia listed here in C. It includes chronic 
forms even though the term is sometimes limited to acute or episodic psychoses. 
It also includes forms in which the schizophrenic symptoms are of brief dura¬ 
tion compared to the affective symptoms or the converse. The term Schizo-af- 
fective Disorder, rather than Schizophrenia, is used to reflect the current 
uncertaintly as to whether this condition is a subgroup of Schizophrenia or 
more closely related to affective illness. 
A through E are required for the episode of illness being considered. 
A. One or more distinct periods with dysphoric mood or pervasive loss of 
interest or pleasure. The disturbance is characterized by symptoms such as the 
following: depressed, sad, blue, hopeless, low, down in the dumps, "don't care 
anymore," or irritable. The disturbance must be a major part of the clinical 
picture during some part of the illness and relatively persistent or occur fre¬ 
quently. It may not necessarily be the most dominant symptom. It does not 
include momentary shifts from one dysphoric mood to another dysphoric mood, 
e.g., anxiety to depression to anger, such as are seen in states of acute psy¬ 
chotic turmoil. If the symptoms in C occur only during periods of alcohol or 
drug use or withdrawal from them, the diagnosis should be Unspecified Func- 
tional Psychosis. 
B. At least five of the following symptoms are required for definite and four 
for probable (for past episodes because of memory difficulty, one less symptom 
is required). 
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(1) Poor appetite or weight loss or increased appetite or weight gain 
(change of one lb. a week over several weeks or ten lbs. a year when not 
dieting). 
(2) Sleep difficulty or sleeping too much. 
(3) Loss of energy, fatigability, or tiredness. 
(4) Psychomotor retardation or agitation (but not mere subjective feeling of 
restlessness or being slowed down). 
(5) Loss of interest or pleasure in usual activities, including social con¬ 
tact or sex (do not include if limited to a period when delusional or 
hallucinating). (The loss may or may not be pervasive.) 
(6) Feelings of self-reproach or excessive inappropriate guilt (either may 
be delusional). 
(7) Complaints or evidence of diminished ability to think or concentrate, 
such as slowed thinking, or indecisiveness (do not include if associated 
with obvious formal thought disorder, or preoccupation with delusions or 
hallucinations). 
(8) Recurrent thoughts of death or suicide, or any suicidal behavior. 
C. At least one of the following is present: 
(1) Delusions of being controlled (or influenced) or of thought broadcast¬ 
ing, insertion, or withdrawal (as defined in this manual). 
(2) Non-affective hallucinations of any type (as defined in this manual) 
throughout the day for several days or intermittently throughout a one 
week period. 
(3) Auditory hallucinations in which either a voice keeps up a running com¬ 
mentary on the subject's behaviors or thoughts as they occur, or two or 
more voices converse with each other. 
(4) At some time during the period of illness had more than one month when 
he exhibited no prominent depressive or manic symptoms but had delusions 
or hallucinations (although typical depressive delusions such as delu¬ 
sions of guilt, sin, poverty, nihilism, or self-deprecation, or halluci¬ 
nations of similar content are not included). 
(5) Preoccupation with a delusion or hallucination to the relative exclusion 
of other symtoms or concerns (.other than typical depressive delusions of 
guilt, sin, poverty, nihilism, or self-deprecation or hallucinations with 
similar content). 
(6) Definite instances of marked formal thought disorder (as defined in this 
manual) accompanied by either blunted or inappropriate affect, delusions 
or hallucinations of any type, or grossly disorganized behavior. 
D. Signs of the illness have lasted at least one week from the onset of a 
noticeable change in the patient's usual condition (current signs of the ill¬ 
ness may not now meet Criteria A, B, or C and may be residual affective or res¬ 
idual schizophrenic symptoms only, such as mood disturbance, blunted or inap¬ 
propriate affect, extreme social withdrawal, mild formal thought disorder, or 
unusual thoughts or perceptual experiences). 
E. Affective symptoms overlap temporally to some degree with an active period 
of schizophrenic-like symptoms (delusions, hallucinations, marked formal 
thought disorder, bizarre behavior, etc.). 
The following qualifying categories should be considered for each subject who 
currently meets the criteria for Probable or Definite Schizo-affective Disor¬ 
der, Depressed Type. 
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3a. Subtypes based on the course of the present period of Schizo-affective 
Disorder. The following four mutually exclusive subtypes should be considered 
for each subject who currently meets the criteria for Probable or Definite 
Schizo-affeetive Disorder. Note: Some subjects diagnosed initially as Acute 
may later show a Subacute, Subchronic, or even Chronic course. 
(1) Acute Schizo-affeetive Disorder: A through C are required. 
A. Sudden onset--less than three months from first signs of increasing psy¬ 
chopathology to any of the core schizophrenic symptoms (criterion C). 
B. Short course--continuously ill with significant signs of Schizophrenia 
for less than three months. 
C. Full recovery from any previous episode. 
(2) Subacute Schizo-affective Disorder: 
Course is closer to that of Acute than that of Chronic Schizo-affective Dis¬ 
order . 
Example: First episode with fairly rapid onset and duration of five 
months. 
Example: Second episode with onset over a period of six months for this 
episode and full recovery from first episode. 
(3) Subchronic Schizo-affeetive Disorder: 
Course is closer to that of Chronic than that of Acute Schizo-affective Dis¬ 
order . 
Example: Significant signs of Schizophrenia more or less continuously 
present for at least the past year. 
Example: Second period following a previous period from which he did not 
fully recover. 
(4) Chronic Schizo-affective Disorder: 
Significant signs of Schizophrenia more or less continuoulsy present for at 
least the last two years. 
3b. Temporal relationship of affective and schizophrenic-like features for 
current episode. 
(1) Mainly schizophrenic: Either A or B. 
A. Core schizophrenic symptoms listed under C in the Schizo-affective cri¬ 
teria were present for at least one week in the absence of manic or 
depressive features. 
B. Prior to the onset of the affective features, subject exhibited the fol¬ 
lowing features which are often associated with Schizophrenia: social 
withdrawal, impairment in occupational functioning, eccentric behavior, 
emotional blunting, or unusual thoughts or perceptual experiences. 
(2) Mainly affective: A and B are required. 
A. Schizophrenic-like symptoms listed under C in the Schizo-affective cri¬ 
teria developed simultaneously with or followed manic or depressive symp¬ 
toms and never were present for a period of at least one week in the 
absence of the manic or depressive symptoms. 
B. Good premorbid social and occupational adjustment 
(3) Other: Does not clearly fit either (1) or (2). 
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3c. Length of time from first signs of increasing psychopathology to any of 
the core schizophrenic symptoms noted in C. (If more than one episode, most 
recent.) 
1. Less than 2 days 
2. Less than 1 week 
3. Less than 1 month 
4. Less than 2 months 
5. More than 2 months 
4. Depressive Syndrome Superimposed on Residual Schizophrenia (Secondary 
Depression) 
This category is to be used when a subject has once met the criteria for a 
period of Schizophrenia from which he did not full recover (and therefore met 
the criteria for Residual Schizophrenia) and who then had and/or now has a 
superimposed depressive syndrome without any activation of psychotice schizo¬ 
phrenic features (i.e., prominent delusions, hallucinations, marked formal 
thought disorder, bizarre behavior, etc.). This category, which represents one 
type of "Secondary Affective Disorder" has been added so that such cases are 
not included within the categories of Major Depressive Disorder of Schizo-af- 
fective Disorder, Depressed Type (although some investigators would consider 
such patients to have one type of Schizo-affeetive Disorder and may wish to 
combine samples). 
Since almost all schizophrenic subjects have depressive features at times, this 
category should be used only if the affective disturbance is (1) sufficiently 
severe to qualify for the full depressive syndrome and (2) prominent and rela¬ 
tively persistent. 
A through C are required for the period of illness being considered. 
A. The period of illness meets the criteria for Residual Schizophrenia. 
B. The period of illness meet the criteria for a depressive syndrome (criteria 
A and B of Major Depressive Disorder). 
C. The depressive syndrome is prominent and relatively persistent for at least 
one week. 
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D. CPZ-Equivalent Conversions 
In order to convert dosage of antipsychotic medications to chlorpromazine (CPZ) 
equivalents, the daily dosage is multiplied by a given factor. The factors 
given by Hollister (1970) were used in all cases except for thiothixene, 
because the conversion factor did not agree well with the one given by Davis 
(1974). An intermediate value was used for this medication. Conversion fac¬ 
tors reported by these two authors are given, as well as the ones used in the 
present study. 
Antipsychotic Present study Hollister Davis 
Haloperidol (Haldol) 50 50 62.5 
Perphenazine (Trilafon) 10 10 11.2 
Chlorpromazine (Thorazine) 1 1 1 
Trifluoperazine (Stelazine) 20 20 35.7 
Thiothixene (Navane) 33 50 19.2 
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E. TSH response curve 
The typical response of TSH to an intravenous supramaximal dose of 500 yg TRH. 
SERUM TSH RESPONSES (MEAN iSE) FOLLOWING AN I.V. BOLUS OF 500 UG TRH IN A 
CROSS-SECTIONAL SAMPLE OF MALE PSYCHIATRIC INPATIENTS 
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F. Data Coding Format 
The variable names used in entering the data into the computer for 
statistical analysis are given below along with the coding key used. 
OBS: Observation number, from 1 to 33. 
ID: Identification number. Corresponds to the number given to the 
patient in the larger study by Wahby et al. 
DX: Diagnosis (by RDC). 
0 = Healthy control 
1 = Schizophrenic, paranoid 
2 = Schizophrenic, other subtypes 
3 = Schizoaffective 
TYPE: Type of schizoaffective disorder (by RDC). 
0 = Not applicable (not schizoaffective) 
1 = Depressed type 
2 = Manic type 
3 = Mixed type 
COURSE: Course of schizoaffective illness (by RDC). 
0 = Not applicable (not schizoaffective) 
1 = Chronic 
2 = Acute 
3 = Not determined 
MOSTLY: Temporal relationship of affective and schizophrenia¬ 
like features for current episode of schizoaffective 
disorder (by RDC). 
0 = Not applicable (not schizoaffective) 
1 = Mainly schizophrenic 
2 = Mainly affective 
AGE: Age of subject in years. 
HEIGHT: Height of subject in inches. 
WEIGHT: Weight of subject in pounds. 
RACE: Race of subject. 
0 = White 
1 = Black 
TT4: Total serum thyroxine of subject in ng/ml. 
FT4: Serum free thyroxine of subject in pU/ml. 
TSHBASE: Baseline serum TSH level in pU/ml. 
PRL: Baseline serum prolactin level in ng/ml. 
DPRLMAX: Maximum APRL in ng/ml. 
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NEURLPT: Type of antipsychotic taken by subject. 
0 = None 
1 = Haloperidol (Haldol) 
2 = Perphenazine (Trilafon) 
4 = Chlorpromazine (Thorazine) 
5 = Trifluoperazine (Stelazine) 
6 = Thiothixene (Navane) 
TOTCPZEQ: Dosage of antipsychotic converted to CPZ equivalents 
according to the conversion factors given in Appendix D. 
DURTX: Duration of antipsychotic treatment in weeks (0 = subject 
not on antipsychotic medication). 
ANTICHO: Type of anticholinergic taken. 
0 = None 
17 = Benztropine (Cogentin) 
18 = Trihexyphenidyl (Artane) 
0THER1 and OTHER2: Any other medications being taken by subject. 
0 = None 
19 = Diphenhydramine (Benadryl) 
24 = Temazepam (Restoril) 
31 = Naproxen (Naprosyn) 
32 = Nadolol (Corgard) 
33 = Furosemide (Lasix) 
38 = Miscellaneous drugs (including tetracycline, guaifenesin, 
methylphenidate, nitroglycerin, and dexbrompheniramine) 
DELTA: ATSHmax in yU/ml. 
KOSTEN: Area under the TSH response curve as calculated by 
Simpson's rule. 
DXG: Diagnostic category of subject. 
1 = Control 
2 = Schizophrenic 
3 = Schizoaffective 
DELTAG: ATSHmax response. 
1 = Blunted (< 6 yU/ml) 
2 = Non-blunted (> 6 yU/ml) 
FACTORG: Study group of subject. 
1 = Healthy controls (Group A) 
2 = Patients on no antipsychotics (Group B) 
3 = Patients on antipsychotics (Group C) 
DPRLG: APRLmax response of subject in ng/ral. 
1 = Less than the median (^30 ng/ml) 
2 = Greater than the median (>30 ng/ml) 
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KOSTENG: Area under TSH response curve group of subject. 
1 = Less than the median (< 250) 
2 = Greater than the median (> 250) 
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G. Raw Data 
(See Appendix F for variable names and codes used; missing value) 
T 
c M H W S 
0 0 E E H 
T u s I I R B 
0 Y R T A G G A T F i A P 
B I D P s L G H H C T T S R 
S D X E E Y E T T E 4 4 j E L 
1 4 2 0 0 0 23 68 172 0 7. ,0 1.24 1 .0 8, .7 
2 10 3 1 1 1 39 70 197 0 7, .7 1.19 3 . 1 13. .0 
3 13 2 0 0 0 51 67 200 0 8. .7 1.26 2 .7 11. .6 
4 17 3 2 1 2 25 69 207 0 10. .9 1.29 4 .6 24, .5 
5 19 3 2 1 2 36 68 165 0 6, .6 1.46 3 .0 11, .0 
6 22 3 1 1 2 35 74 238 0 7. .9 1.30 3 .5 3, .0 
7 24 0 0 0 0 38 72 205 0 9. . 1 1.77 3 .3 8. .0 
8 25 2 0 0 0 27 70 155 1 9. .3 1.42 3 .0 7. .0 
9 27 3 3 1 2 45 76 176 0 5, .6 1.25 4 . 7 5. .8 
10 34 2 0 0 0 52 70 200 0 6. .5 1.07 2 . 7 2. ,0 
11 44 3 3 1 2 37 72 175 0 8. .2 1.53 3 .2 8. .5 
12 47 3 2 3 1 37 69 185 1 7. .5 1.28 3 .6 8. .8 
13 51 2 0 0 0 23 76 187 0 7. .2 1.66 4 .5 15. ,8 
14 61 0 0 0 0 50 74 313 0 7. . 1 1.42 5 .0 5. ,8 
15 63 2 0 0 0 58 72 190 0 8. .3 1.55 3 .4 3. .2 
16 64 3 3 3 1 42 73 188 1 5. .3 1.36 4 .2 14, .6 
17 67 2 0 0 0 37 71 190 1 6. .2 1.16 2 .7 7. ,0 
18 72 0 0 0 0 22 72 205 0 7. .5 1.67 3 .5 16, .0 
19 76 0 0 0 0 54 68 240 0 8. . 1 1.33 2 .8 3. .6 
20 85 0 0 0 0 30 70 259 0 6. .2 1.60 2 .4 10. .7 
21 86 2 0 0 0 59 70 190 0 6. .7 1.37 1 .9 6. .6 
22 89 0 0 0 0 48 68 240 0 6. . 7 1.10 2 .7 5, .4 
23 93 2 0 0 0 32 66 185 0 8. .6 1.64 1 .7 11. .0 
24 94 1 0 0 0 22 68 140 0 6, .6 1.45 3 .0 14, ,0 
25 95 0 0 0 0 27 70 150 0 7, .7 1.66 1 . 1 5 , .4 
26 97 0 0 0 0 52 69 162 0 6, . 1 1.26 4 .3 3, .3 
27 99 0 0 0 0 33 76 175 1 12, . 1 1.50 3 .9 12. .2 
28 100 0 0 0 0 37 65 150 0 7, .4 1.42 2 .6 10. .0 
29 101 0 0 0 0 23 71 190 0 8, .3 1.50 4 .4 
30 102 0 0 0 0 23 72 195 0 8 .8 1.55 4 .0 
31 103 0 0 0 0 46 70 175 0 8 .5 1.60 4 .5 
32 104 2 0 0 0 35 71 154 0 7. .7 1.45 4 .3 
33 105 0 0 0 0 26 70 150 0 9 . 1 1.70 2 .5 
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T 
D N 0 A 
P E T N 
R U C D T 
L R P U I 
0 M L Z R C 
B A P E T H 
S X T Q X 0 
1 51. 1 0 0 0 0 
2 57. ,0 2 480 7 17 
3 67. 0 5 300 468 17 
4 45. .5 4 570 312 0 
5 12. ,5 2 400 1 17 
6 18. ,0 0 0 0 0 
7 15. ,5 0 0 0 0 
8 18. ,2 0 0 0 0 
9 22. , 7 0 0 0 0 
10 20. .0 0 0 0 0 
11 27. ,5 2 480 3 17 
12 21. ,2 0 0 0 0 
13 21. ,7 2 240 3 17 
14 5. , 7 0 0 0 0 
15 9. .0 0 0 0 0 
16 43, ,4 2 560 28 18 
17 89, .0 4 600 56 0 
18 34. .0 0 0 0 0 
19 29, .4 0 0 0 0 
20 18, .0 0 0 0 0 
21 6. .2 1 500 1 0 
22 13, .6 0 0 0 0 
23 10 .5 6 1650 676 17 
24 57, .0 0 0 0 0 
25 42, .6 0 0 0 0 
26 46 .9 0 0 0 0 
27 94 .8 0 0 0 0 
28 45 .0 0 0 0 0 
29 0 0 0 0 
30 0 0 0 0 
31 0 0 0 0 
32 4 500 • . 
33 0 0 0 0 
0 
T D 
K 
0 
D 
E 
F 
A 
C D 
K 
0 
S 
H E S L T P T 
E L T D T 0 R E 
R T E X A R L N 
2 A N G G G G G 
0 7.5 351 2 2 2 2 2 
0 6.5 221 3 2 3 2 1 
0 5.9 214 2 1 3 2 1 
0 7.9 284 3 2 3 2 2 
0 8.0 308 3 2 3 1 2 
0 6.2 182 3 2 2 1 1 
0 11.9 290 1 2 1 1 2 
0 5.2 189 2 1 2 1 1 
0 12.5 344 3 2 2 1 2 
0 3.6 122 2 1 2 1 1 
19 11.5 290 3 2 3 1 2 
0 6.8 212 3 2 2 1 1 
0 6.3 196 2 2 3 1 1 
31 5.0 140 1 1 1 1 1 
0 4.0 126 2 1 2 1 1 
0 14.3 401 3 2 3 2 2 
0 7.9 288 2 2 3 2 2 
0 9.5 295 1 2 1 2 2 
0 14.8 392 1 2 1 1 2 
32 14.2 365 1 2 1 1 2 
0 4.0 115 2 1 3 1 1 
0 11.8 344 1 2 1 1 2 
0 5.1 133 2 1 3 1 1 
0 21.0 669 2 2 2 2 2 
0 5.3 133 1 1 1 2 1 
0 20.5 529 1 2 1 2 2 
0 6.6 185 1 2 1 2 1 
0 7.4 203 1 2 1 2 1 
9.4 266 1 2 1 1 2 
6.6 167 1 2 1 1 1 
8.6 232 1 2 1 1 1 
14.0 428 2 2 3 1 2 
7.3 187 1 2 1 1 1 
0 
T 
H 
E 
R 
1 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
24 
0 
0 
33 
0 
0 
0 
38 
38 
33 
38 
38 
0 
0 
38 
0 
0 
0 
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